

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

ANNEX 1B

Index No	Chemical name	Notes related to substances	EC No	CAS No	Classification	Labelling	Concentration Limits	Notes related to preparations
003-003-0025	methylpropyl)lithium; isobutyllithium		440-620-2	920-36-5	F; R15-17 R14 C; R35 R67 N; R50-53	F; C; N R: 14/15-17-35-67-50/53 S: (1/2-)6-16-26-30-33-36/37/39-43-45-60-61		
005-013-0016	dimethylmethoxyborane		425-380-9	7397-46-8	F; R17 Xn; R20/21/22-48-22-21/48-22-21/22-34-43-48/22-53 C; R34 R43 R53	F; C R: 14/15-17-35-67-50/53 S: (1/2-)6-26-36/37/39-43-45-61		
005-014-0040	formylphenylboronic acid		438-670-5	587199-17	R43	Xi R: 43 S: (2-)24-37		
005-017-0067	lithium perborate; [1] perboric acid, sodium salt; [2] perboric acid, sodium salt, monohydrate; [3] sodium peroxometaborate; [4] perboric acid (HBO(O ₂)), sodium salt, monohydrate; [5] sodium peroxoborate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter	E	239-172-9 234-390-0 - [3] 231-556-4 - [5]	[1] 20-21-01 [2] 38-47-91 12040-72-4 [3] 2-04-41 10332-33-5	[1] R8 [2] R7 [3] C13; [4] R61 [5] R51 Cat. 3; R62 Xn; R22 Xi; R37-41	O; T R: 61-8-22-37-41-62 S: 53-45	C ≥ 25 %: T; R61-62-37-41-62 22 % ≤ C < 25 %: T; R61-37-41-62 20 % ≤ C < 20 %: T; R61-36/37-62 14 % ≤ C < 14 %: T; R61-62 6,5 % ≤ C < 9 %: T; R61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	of below 50 µm]						
005-017-01	sodium perborate; [1] perboric acid, sodium salt; [2] perboric acid, sodium salt, monohydrate; [3] sodium peroxometaborate; [4] perboric acid (HBO(O ₂)), sodium salt, monohydrate; [5] sodium peroxoborate; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	E	239-172-9 [1] 234-390-0 [2] - [3] 231-556-4 [4] - [5]	120-21-6 [1] 138-47-9 [2] 12040-72-1 [3] 12-04-4 [4] 10332-33-1 [5]	Repr. Cat. 3; R62 T; R23 Xn; R22 Xi; R37-41	O; T R: 61-8-22-2 S: 53-45	C ≥ 25 %: T; R61-41-62 22 % ≤ C < 25 %: T; R61-20-37-41-62 20 % ≤ C < 22 %: T; R61-20-36/37-62 14 % ≤ C < 20 %: T; R61-20-36-62 9 % ≤ C < 14 %: T; R61-20-62 6,5 % ≤ C < 9 %: T; R61-20 3 % ≤ C < 6,5 %: Xn; R20
005-018-00	perboric acid (H ₃ BO ₂ (O ₂)), monosodium salt trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O ₂)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate;		- [1] - [2] - [3]	13517-20-1 [1] 37244-98-1 [2] 10486-00-1 [3]	Repr. Cat. 2; R61 Repr. Cat. 3; R62 Xi; R37-41	T R: 61-37-41-62 S: 53-45-47	C ≥ 36 %: T; R61-37-41-62 22 % ≤ C < 36 %: T; R61-36/37-62 20 % ≤ C < 22 %: T; R61-37-62 14 % ≤ C < 20 %: T; R61-62 10 % ≤ C < 14 %: T; R61

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]						
005-018-01 X	perboric acid (H3BO2(O2)), monosodium salt, trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	E	- [1] - [2] - [3]	13517-20- 37244-98- 10486-00-	Repr. Cat. 2; R61 Repr. Cat. 3; R62 Xn; R20 Xi; R37-41	T R: 61-20-37- S: 53-45-47	C ≥ 36 %: T; R61-20-37-41-62 25 % ≤ C < 36 %: T; R61-20-36/37-62 22 % ≤ C < 25 %: T; R61-36/37-62 20 % ≤ C < 22 %: T; R61-37-62 14 % ≤ C < 20 %: T; R61-62 10 % ≤ C < 14 %: T; R61
006-097-00	6-phenyl-3-(p-toluenesulfonyl)urea			424-620-1 13909-63-	Xn; R22-48/22 R52-53	Xn R: 22-48/22-52/53 S: (2-)22-36-61	
006-098-00	tert-butyl (1R,5S)-3-azabicyclo[3.1.0]hex-6-ylcarbamate			429-170-8 134575-1	Xn; R22-48/22 Xi; R41 R43	Xn R: 22-41-43-48/22 S: (2-)22-26-36/37/39	
006-099-00	7-(p-toluenesulfonyl)-N			432-520-2 2232938-4	N; R51-53	N R: 51/53 S: 22-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

								'-(3-(<i>p</i> -toluenesulfonyloxy)phenyl)urea; 3-({[(4-methylphenyl)sulfonyl]carbonyl}amino)phenyl 4-methylbenzenesulfonate
006-101-006			423-070-8		R53	R: 53 S: 61		Mixture of: <i>N,N''</i> -(methylenedi-4,1-phenylene)bis[<i>N'</i> -phenylurea]; <i>N</i> -(4-[[4-[(phenylamino)carbonyl]amino]phenylmethyl]phenyl]- <i>N'</i> -cyclohexylurea; <i>N,N''</i> -(methylenedi-4,1-phenylene)bis[<i>N'</i> -cyclohexylurea]
006-102-004	E		432-750-3		Carc. Cat. 2; R45 Muta. Cat. 2; R46 Xn; R22-48/22 R43 N; R51-53	T; N R: 45-46-22-43-48/22-51/53 S: 53-45-61		hexyl- <i>N</i> -ethoxycarbonylthiocarbamate
006-103-007			445-760-8		Xi; R41 R42 N; R50-53	Xn; N R: 41-42-50/53 S: (2-)22-26-39/45-60-61	C ≥ 10 %: Xn, N; R41-42-50/53 < 10 %: Xn, N; R36-42-50/53 1 % ≤ C < 5 %: Xn, N; R42-50/53 0,25 % ≤ C < 1 %: N; R50/53 0,025 % ≤ C <	<i>N,N''</i> -(methylenedi-4,1-phenylene)bis[<i>N'</i> -octyl]urea

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						0,25 %: N; R51/53 0,0025 ≤ C < 0,025 %: R52/53	
007-029-001	Diethylmethylamine hydroxide	419-400-595500-19			Xn; R21/22 C; R35	C R: 21/22-35 S: (1/2-)26-36/37/39-45	
012-004-001 X	Aluminium-magnesium-carbonate-hydroxide-perchlorate-hydrate	422-150-1	—		N; R50-53	N R: 50/53 S: 60-61	
014-036-004 X	(4-ethoxyphenyl)(3-(4-fluoro-3-phenoxyphenyl)propyl)dimethylsilane	405-020-7105024-66			Repr.Cat.2 R60 N; R50-53	T; N R: 60-50/53 S: 53-45-60-61	C ≥ 0,5 %: T, N; R60-50/53 0,025 % ≤ C < 0,5 %: N; R50/53 0,0025 % ≤ C < 0,025 %: N; R51/53 0,00025 % ≤ C < 0,0025 %: R52/53
014-037-005	butanone- <i>O,O'</i> -(phenylsilylidyne)trioxime	433-360-634036-80			Xn; R48/22 R43 R52-53	Xn R: 43-48/22-52/53 S: (2-)36/37-61	
014-038-003	(triethoxysilyl)propyl)octanethioate	436-690-9220727-26			R43	Xi R: 43 S: (2-)24-37	
014-039-002	(2,6-dimethylbut-2-yl)-trimethoxysilane	439-360-2142877-45			Xi; R38-41 R52-53	Xi R: 38-41-52/53	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					S: (2-)26-37/39-61		
014-041-00	N- bis(trimethylsilyl)aminopropylmethyl-diethyl-trisilane	445-890-5201290-0			Xn; R22 R43	Xn R: 22-43 S: (2-)24-37	
014-042-00	Mixture of: O,O' ,O'',O'''- silanetetrayl tetrakis(4- methyl-2- pentanone oxime) (3 stereoisomers)	423-010-0			Xi; R41	Xi R: 41 S: (2-)26-39	
014-043-00	Reaction product of amorphous silica (50-85 %), butyl (1- methylpropyl) magnesium (3-15 %), tetraethyl orthosilicate (5-15 %) and titanium tetrachloride (5-20 %)	432-200-2			F; R11 Xi; R37/38-41 R52-53	F; Xi R: 11-37/38-41-52/53 S: (2-)6-26-36/39-61	
014-044-00	[4'- acetoxy-3'- methoxyphenyl) propyl]trimethoxysilane	433-050-0			N; R51-53	N R: 51/53 S: 61	
014-045-00	magnesium sodium fluoride silicate	442-650-1			Xn; R48/20	Xn R: 48/20 S: (2-)22-36	
015-190-00	[2,4- dicumylphenyl) neopentyl diphosphite; 3,9- bis[2,4- bis(1- methyl-1- phenylethyl)phenoxy]-2,4,8,10-	421-920-2154862-4			R53	R: 53 S: 61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	tetraoxa-3,9-diphosphaspiro[5.5]undecane						
015-191-006	decyldiphenyl phosphate	431-760-527460-02			Xi; R38 R52-53	Xi R: 38-52/53 S: (2-)37-61	
015-192-001	trakis(2,6-dimethylphenyl)- <i>m</i> -phenylene biphosphate	432-770-2139189-30			R43 R53	Xi R: 43-53 S: (2-)24-37-61	
015-193-007	phenyl(phenylmethyl)-1,1,2,2,3,3,4,4,4-nonafluoro- <i>N</i> -methyl-1-butanefulfonamide (1:1)	442-966-733235-93			R33 R25 Xi; R41 N; R50-53	T; N R: 25-41-50/53 S: (1/2-)26-39-45-60-61	
015-194-002	tert-butylphosphonium nonafluorobutane-1-sulfonate	444-440-5220689-12			Xn; R22 R52-53	Xn R: 22-52/53 S: (2-)61	
015-195-008	mixture of: potassium <i>o</i> -toluenephosphonate; potassium <i>m</i> -toluenephosphonate; potassium <i>p</i> -toluenephosphonate	433-860-4—			Xi; R36 R43 R52-53	Xi R: 36-43-52/53 S: (2-)24-26-37-61	
015-196-003	mixture of: dimethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate; diethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate; methyl ethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate	435-960-3—			Carc.Cat.2 R45 Muta.Cat.2 R46 R43	T R: 25-46-43 S: 53-45	
015-197-009	(2,4,4-trimethylpentyl)dithiophosphonic acid	420-160-9107667-02			R10 T; R23 Xn; R22 C; R34	T; N R: 10-22-23-34-51/53 S: (1/2-)9-26-36/37/39-45-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					N; R51-53		
015-198-0044	(phenylbutyl)phosphinic acid		420-450-586552-32		Carc. Cat. 3 R40 Xi; R41	Xn R: 40-41 S: (2-)23-26-36/37/39	
016-094-0066	sulfur		231-722-67704-34-9		Xi; R38	Xi R: 38 S: (2-)46	
016-097-0008	amino-2-methyl-2-propanethiol hydrochloride		434-480-132047-53		Xn; R22 C; R34 R43 R52-53	C R: 22-34-43-52/53 S: (1/2-)22-26-36/37/39-45-61	
017-009-0118	ammonium perchlorate; [containing < 80 % of 0-30 µm particles]		232-235-17790-98-9		E; R2 O; R9	E R: 2-9 S: (2-)14-16-36/37	
022-004-0066	potassium titanium oxide (K ₂ Ti ₆ O ₁₃)		432-240-012056-51		Carc. Cat. 3 R40	Xn R: 40 S: (2-)22-36/37	
022-005-0047	(1,1-dimethylethyl)-1,1-dimethyl-1-[(1,2,3,4,5-η)-2,3,4,5-tetramethyl-2,4-cyclopentadien-1-yl]silanaminato(2-)-κN [(1,2,3,4-η)-1,3-pentadiene]-titanium		419-840-8169104-7		EF R11 C; R34 R43 R53	F; C R: 11-34-43-53 S: (1/2-)6-9-16-26-36/37/39-45-61	
028-002-0114	nickel powder; [particle diameter < 1 mm]		231-111-47440-02-0		Carc. Cat. 3; R40 T; R48/23 R43 R52-53	T R: 40-43-48/23-52/53 S: (2-)36/37/39-45-61	
028-013-0017	nickel matte	E, H	273-749-669012-50		Carc. Cat. 1; R49 T; R48/23	T; N R: 49-43-48/23-50/53	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					R43 N; R50-53	S: 53-45-60-61	
028-014-0612	0612 slimes and sludges, copper electrolytic refining, decopperised, nickel sulfate	E	295-859-392129-57	292129-57	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 Xn; R20/22 Xi; R38 R42/43 N; R50-53	T; N R: 49-61-20/22-38-42/43-48/23-68-50/53 S: 53-45-60-61 C ≥ 25 %: R49-61-20/22-38-42/43-48/23-68-50/53 20 % ≤ C < 25 %: T, N; R49-61-38-42/43-48/23-68-51/53 2,5 % ≤ C < 20 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-015-0618	0618 slimes and sludges, copper electrolyte refining, decopperised	E, H	305-433-194551-87	194551-87	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 1; R61 Repr. Cat. 3; R62 T; R48/23	T; N R: 49-61-42/43-48/23-62-68-50/53 S: 53-45-60-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					R42/43 N; R50-53		
028-016-0010	nickel diperchlorate; perchloric acid, nickel(II) salt	E, H	237-124-11	13637-71	Car. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 C; R34 R42/43 N; R50-53	T; N R: 49-61-34-42/43-48/23-68-50/53 S: 53-45-60-61	$C \geq 25\%$; R49-61-34-42/43-48/23-68-50/53 $61\% \leq C < 25\%$; T, N; R49-61-34-42/43-48/23-68-51/53 $2,5\% \leq C < 5\%$; T, N; R49-61-36/38-42/43-48/23-68-51/53 $1\% \leq C < 2,5\%$; T; R49-61-36/38-42/43-48/23-68-52/53 $0,5\% \leq C < 1\%$; T; R49-61-43-48/20-52/53 $0,25\% \leq C < 0,5\%$; T; R49-43-48/20-52/53 $0,1\% \leq C < 0,25\%$; T; R49-43-48/20 $0,01\% \leq C < 0,1\%$; Xi; R43
028-017-0010	nickel dipotassium bis(sulfate); [1] diammonium nickel bis(sulfate) [2]	E, H	237-563-91	13842-46-239-793-21	Car. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 Xn; R20/22 R42/43 N; R50-53	T; N R: 49-61-20/22-42/43-48/23-68-50/53 S: 53-45-60-62	$C \geq 25\%$; R49-61-20/22-42/43-48/23-68-50/53 $62\% \leq C < 25\%$; T, N; R49-61-42/43-48/23-68-51/53 $1\% \leq C < 2,5\%$; T; R49-61-42/43-48/23-68-52/53 $0,5\% \leq C < 0,1\%$;

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

							1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-018-00	Nickel bis(sulfamidate); nickel sulfamate	E, H	237-396-1	13770-89	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-019-00 X	Nickel bis(tetrafluoroborate)	E, H	238-753-4	14708-14	Carc. Cat. 1; R49 Muta. Cat. 3; R68	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53		2,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; 49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-021-0010	nickel diformate; [1] formic acid, nickel salt; [2] formic acid, copper nickel salt [3]	E, H	222-101-03349-06-2 239-946-613843-02-4 268-755-068134-59-8	Chf. Cat. R49 M Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-21	C ≥ 25 %: 49-61-42/43-48/23-68-50/53 R49-61-42/43-48/23-68-50/53 0,5 % C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5%: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %:		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

							T; R49-43-48/20 0,01 % ≤ C 0,1 %: Xi; R43
028-022-0016	nickel di(acetate); [1] nickel acetate [2]	E, H	206-761-7373-02-4 239-086-112998-37	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 Xn; R20/22 R42/43 N; R50-53	T; N R: 49-61-20/22-42/43-48/23-68-50/53 S: 53-45-60-02,5 %	C ≥ 25 %: R49-61-20/22-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N: R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20	
028-024-0017	nickel dibenzoate	E, H	209-046-8553-71-9	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-02,5 %	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N: R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C <	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

							1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-025-0012	nickel bis(4-cyclohexylbutyrate)	E, H	223-463-23906-55-6	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-026-0018	nickel(II) stearate; nickel(II) octadecanoate	E, H	218-744-12223-95-2	Carc. Cat. 1; R49 Muta. Cat. 3; R68	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53		2,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-027-0013	nikel dilactate	E, H	—	16039-61-6	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-2	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %:	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

							T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-028-0010	nickel(II) octanoate	E, H	225-656-74995-91-9	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat 2; R61 T; R48/23 C; R35 R42/43 N; R50-53	T; C; N R: 49-61-35-42/43-48/23-68-50/53 S: 53-45-60-60	C ≥ 25 %: R49-61-35-42/43-48/23-68-50/53 10 % ≤ C < 25 %: T, C, N; R49-61-35-42/43-48/23-68-51/53 5 % ≤ C < 10 %: T, N; R49-61-34-42/43-48/23-68-51/53 2,5 % ≤ C < 5 %: T, N; R49-61-36/38-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-36/38-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-029-0014	nickel difluoride; [1] nickel dibromide; [2] nickel diiodide; [3]	E, H	233-071-310028-18-01 236-665-013462-88-9; R49 236-666-613462-90-1 - [4] 11132-10-814	Carc. Cat. 1; R49 Muta. Cat. 3; R68	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-21	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 2,5 % ≤ C < 25 %:	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	nickel potassium fluoride [4]				Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; 49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; 49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-030-00 X	nickel hexafluorosilicate	E, H	247-430-7 26043-11	6 43-11	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						0,01 % ≤ C < 0,1 %: Xi; R43
028-031-0016	nickel selenate	E, H	239-125-2	15060-62	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61 C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-032-0010	nickel hydrogen phosphate; [1] nickel bis(dihydrogen phosphate); [2] trinickel bis(orthophosphate); [3] dinickel diphosphate; [4] nickel bis(phosphinate); [5] nickel phosphinate; [6] phosphoric acid, calcium	E, H	238-278-2 242-522-3 233-844-5 238-426-6 238-511-8 252-840-4	4332-34-1 8718-11-1 0381-36-9 4448-18-4 4507-36-4 6026-88-7 17169-61-8 19372-20-4	Carc. Cat. 1; R49 T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61 N[6] R[50]53 [8]	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	nickel salt; [7] diphosphoric acid, nickel(II) salt [8]						
028-033-0016	nickel hexacyanoferrate	E, H	—	74195-78-0	Carc. Cat. 1; R49 T; R48/23 R42/43 N; R50-53	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	
028-034-0016	nickel dicyanide	E, H	209-160-8	557-19-7	Carc. Cat. 1; R49 T; R48/23 R42/43 R32 N; R50-53	T; N R: 49-32-42/43-48/23-50/53 S: 53-45-60-61	
028-035-0017	nickel chromate	E, H	238-766-5	14721-18-0	Carc. Cat. 1; R49 T; R48/23 R42/43 N; R50-53	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	
028-036-0012	nickel(II) silicate; [1] dinickel orthosilicate; [2] nickel silicate (3:4); [3] silicic acid, nickel salt; [4] trihydrogen hydroxybis[orthosilicato(4-)]trinickelate(3-) [5]	E, H	244-578-4 237-411-1 250-788-7 253-461-7 235-688-3	411784-78-0 [3]775-54-7 [3]748-25-1 [3]21-15-6 [3]19-85-6	Carc. Cat. 1; R49 T; [3] R48/23 R45 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-037-0018	nickel hexacyanoferrate	E, H	238-946-3	14874-78-0	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-038-0013	nickel bis(arsenate);	E, H	236-771-7	13477-70-0	Carc. Cat. 1; R45	T; N	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	nickel(II) arsenate				T; R48/23 R43 N; R50-53	R: 45-43-48/23-50/53 S: 53-45-60-61	
028-039-0010	nickel oxalate; [1] oxalic acid, nickel salt [2]	E, H	208-933-747-67-1 243-867-240343-06	147-67-1 243-06	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-040-0014	nickel telluride	E, H	235-260-612142-88	12142-88	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-041-001X	nickel tetrasulfide	E, H	—	12137-12	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-042-0015	nickel bis(arsenite)	E, H	—	74646-29	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-043-0000	cobalt nickel gray periclase; C.I. Pigment Black 25; C.I. 77332; [1] cobalt nickel dioxide; [2] cobalt nickel oxide [3]	E, H	269-051-648186-89 261-346-818391-45- - [3]	648186-89 12737-30	Carc. Cat. 1; R49 T; R48/23 R43	T R: 49-43-48/23 S: 53-45	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

028-044-0016	Nickel tin trioxide; nickel stannate	E, H	234-824-9	12035-38	Carc. Cat. 1; R49 T; R48/23 R43	T R: 49-43-48/23 S: 53-45		
028-045-0016	Nickel triuranium decaoxide	E, H	239-876-6	15780-33	Carc. Cat. 1; R49 T; R48/23 R43	T R: 49-43-48/23 S: 53-45		
028-046-0017	Nickel dithiocyanate	E, H	237-205-1	13689-92	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 R32 N; R50-53	T; N R: 49-61-32-42/43-48/23-68-50/53 S: 53-45-60-61 5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-61-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43		
028-047-0012	Nickel dichromate	E, H	239-646-5	15586-38	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61 5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					R42/43 N; R50-53	1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; 49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1% ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C 0,1 %: Xi; R43	
028-048-0018	Nickel(II) selenite	E, H	233-263-7	10101-96	Carc. Cat. 1; R49 T; R48/23 R42/43 N; R50-53	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	
028-049-0018	Nickel selenide	E, H	215-216-2	1314-05-2	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-050-0019	picric acid, lead nickel salt	E, H	—	68130-19	Carc. Cat. 1: R49 Repr. Cat. 1: R61 Repr. Cat. 3; R62 T; R48/23 R43 N; R50-53	T; N R: 49-61-43-48/23-62-50/53 S: 53-45-60-61	
028-051-0014	Nickel diarsenide; [1]	E, H	235-103-1 248-169-1	12068-61 12016-75	Carc. Cat. 1; R49 T; R49	T; N	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	nickel arsenide [2]				T; R48/23 R43 N; R50-53	R: 49-43-48/23-50/53 S: 53-45-60-61	
028-052-00 X	nickel barium titanium primrose priderite; C.I. Pigment Yellow 157; C.I. 77900	E, H	271-853-668610-24	61952-43-9; R49 T; R48/23 R43	Carc. Cat. 1: R49 T; R48/23 R43	T R: 49-43-48/23 S: 53-45	
028-053-00	nickel dichlorate; [1] nickel dibromate; [2] ethyl hydrogen sulfate, nickel(II) salt [3]	E, H	267-897-061952-43-9; 238-596-112350-87-9; 275-897-713720-48-1	61952-43-9; R49 Mut. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	Carc. Cat. 1: R49 Mut. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61 C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N: R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T: R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T: R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-054-00	nickel(II) trifluoroacetate; [1] nickel(II) propionate; [2]	E, H	240-235-816083-14-0 222-102-63349-08-4 254-642-319819-65-3 242-533-318721-51-2	61952-43-9; R49 Carc. Cat. 1: R49 Carc. Cat. 2: R49 Carc. Cat. 3: R49 Carc. Cat. 4: R49	Carc. Cat. 1: R49 Carc. Cat. 2: R49 Carc. Cat. 3: R49 Carc. Cat. 4: R49	T; N R: 49-61-42/43-48/23-68-50/53 R49-61-42/43-48/23-68-50/53	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

nickel	242-161-1 [15]	283-82-5 [15]	M [5]	S:	2,5 %
bis(benzenesulfonate)	245-119-0 [16]	105-92-6 [16]	C [3];	53-45-60-61	C <
nickel(II)	224-699-9 [17]	434-16-4 [17]	B [6]		25 %:
hydrogen	231-480-1 [18]	80-31-6 [18]	pr.		T, N;
citrate; [4]	301-323-2 [19]	983-68-7 [19]	C [2];		R49-61-42/43-48/23-68-51/53
citric	249-555-2 [20]	17-63-6 [20]	R [10]		1 % ≤ C
acid,	248-585-3 [21]	7-46-3 [21]	T [11]		< 2,5 %:
ammonium	284-349-6 [22]	483-2-37 [22]	R [23]		T;
nickel	300-094-6 [23]	120-10-6 [23]	R [24]		R49-61-42/43-48/23-68-52/53
salt; [5]	287-468-8 [24]	408-43-6 [24]	N [14]		0,5 %
citric	287-469-7 [25]	508-44-7 [25]	R [53]		≤ C <
acid,	257-447-1 [26]	18-56-5 [26]	T [16]		1 %: T;
nickel	300-093-0 [27]	120-09-3 [27]	R [17]		R49-61-43-48/20-52/53
salt; [6]	276-205-6 [28]	7-07-8 [28]	R [18]		0,25 %
nickel	258-051-1 [29]	25-25-9 [29]	R [19]		≤ C <
bis(2-	237-138-8 [30]	34-40-5 [30]	R [20]		0,5 %:
ethylhexanoate); [7]	287-470-2 [31]	208-45-8 [31]	R [21]		T;
2-	287-471-8 [32]	208-46-9 [32]	R [22]		R49-43-48/20-52/53
ethylhexanoic	284-347-5 [33]	23-35-7 [33]	R [23]		0,1 %
acid,	284-351-7 [34]	23-39-1 [34]	R [24]		≤ C <
nickel	285-698-7 [35]	25-77-9 [35]	R [25]		0,25 %:
salt; [8]	285-909-2 [36]	266-19-4 [36]	R [26]		T;
dimethylhexanoic	284-348-0 [37]	23-36-8 [37]	R [27]		R49-43-48/20
acid	287-592-6 [38]	23-28-6 [38]	R [28]		0,01 %
nickel	294-302-1 [39]	297-41-5 [39]	R [29]		≤ C <
salt; [9]	283-972-0 [40]	76-45-4 [40]	R [30]		0,1 %:
nickel(II)	- [31]	72319-19-8 [31]	R [31]		Xi; R43
isooctanoate; [10]					
nickel					
isooctanoate; [11]					
nickel					
bis(isononanoate); [12]					
nickel(II)					
neononanoate; [13]					
nickel(II)					
isodecanoate; [14]					
nickel(II)					
neodecanoate; [15]					
neodecanoic					
acid,					
nickel					
salt; [16]					
nickel(II)					
neoundecanoate; [17]					
bis(D-					
gluonato- <i>O</i> ¹ , <i>O</i> ²)nickel; [18]					
nickel					
3,5-					
bis(<i>tert</i> -					
butyl)-4-					
hydroxybenzoate					
(1:2); [19]					

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	nickel(II) palmitate; [20] (2-ethylhexanoato-O) (isononanoato-O)nickel; [21] (isononanoato-O) (isooctanoato-O)nickel; [22] (isooctanoato-O) (neodecanoato-O)nickel; [23] (2-ethylhexanoato-O) (isodecanoato-O)nickel; [24] (2-ethylhexanoato-O) (neodecanoato-O)nickel; [25] (isodecanoato-O) (isooctanoato-O)nickel; [26] (isodecanoato-O) (isononanoato-O)nickel; [27] (isononanoato-O) (neodecanoato-O)nickel; [28] fatty acids, C ₆₋₁₉ -branched, nickel salts; [29] fatty acids, C ₈₋₁₈ and C ₁₈ -unsaturated, nickel salts; [30] 2,7-naphthalenedisulfonic acid, nickel(II) salt; [31]							
028-055-0016	nickel(II) sulfite; [1] nickel tellurium trioxide; [2] nickel tellurium tetraoxide; [3] molybdenum nickel hydroxide oxide phosphate [4]	E, H	231-827-7715 239-967-0128 239-974-9138 268-585-7681	231-827-7715 239-967-0128 239-974-9138 268-585-7681	231-827-7715 239-967-0128 239-974-9138 268-585-7681	Chc. Cat. T; N R: R49 S: 49-42/43-48/23-50/53 R42/43 S: 53-45-60-61 N; R50-53		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

028-056-00	Nickel boride (NiB); [1] dinickel boride; [2] trinickel boride; [3] nickel boride; [4] dinickel silicide; [5] nickel disilicide; [6] dinickel phosphide; [7] nickel boron phosphide [8]	E, H	234-493-0 [2007-00-1] 234-494-6 [2007-01-1] 234-495-1 [2007-02-1] 235-723-2 [2019-90-8] 235-033-1 [2059-14-8] 235-379-3 [201-89-7] 234-828-0 [2035-64-8] - [8] 65229-23-4 [8]	2007-00-1 2007-01-1 2007-02-1 2019-90-8 2059-14-8 201-89-7 2035-64-8 65229-23-4	Cat. Cat. R49 T3 R48/23 R43 N6 R50/53 R48	T; N R: 49-43-48/23-50/53 S: 53-45-60-61		
028-057-00	Nickel tetraoxide; [1] nickel titanium trioxide; [2] nickel titanium oxide; [3] nickel divanadium hexaoxide; [4] cobalt dimolybdenum nickel octaoxide; [5] nickel zirkonium trioxide; [6] molybdenum nickel tetraoxide; [7] nickel tungsten tetraoxide; [8] olivine, nickel green; [9] lithium nickel dioxide; [10] molybdenum nickel oxide; [11]	Li, H	234-454-8 [2004-35-2] 234-825-4 [2035-39-1] 235-752-0 [2053-76-8] 257-970-5 [2012-12-8] 268-169-5 [2016-03-8] 274-755-1 [2092-93-2] 238-034-5 [2077-55-0] 238-032-4 [2077-51-6] 271-112-7 [2015-84-4] - [10] 12031-65-1 [10] - [11] 12673-58-4 [11]	2004-35-2 2035-39-1 2053-76-8 2012-12-8 2016-03-8 2092-93-2 2077-55-0 2077-51-6 2015-84-4 12031-65-1 12673-58-4	Cat. Cat. R49 S3 R48/23 R43 2 6 7 8 9 10 11	T R: 49-43-48/23 S: 53-45		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

028-058-00	002 Salt lithium nickel oxide	E	442-750-5	—	Carc. Cat. 1; R49 T+; R26 T; R48/23 R43 N; R50-53	T+; N R: 49-26-43-48/23-50/53 S: 53-45-60-61	
029-014-00	005 Mixture of: 2,2'- [[<i>cis</i> -1,2- cyclohexanediylbis(nitrilomethylidene)]bis[phenolate]] (2-) <i>N,N</i> ' <i>O,O</i> '- copper complex; 2,2'- [[<i>trans</i> -1,2- cyclohexanediylbis(nitrilomethylidyne)]bis[phenolate]] (2-) <i>N,N</i> ' <i>O,O</i> '- copper complex		419-610-7	171866-2	Xn; R48/22 N; R51-53	Xn; N R: 48/22-51/53 S: (2-)22-36-61	
030-012-00	001 Aluminium- magnesium- zinc- carbonate- hydroxide		423-570-6	169314-8	R52-53	R: 52/53 S: 61	
030-015-00	008 Zinc(2+)bis(hexacyano)borate(3-)diacetate		440-060-9	—	N R51-53	N R: 51/53 S: 61	
042-005-00	001 Mixture of: mono- and di- glycerols of canola oil; canola oil acid amide of branched 1,3- propanediamine, <i>N</i> - [3- (tridecyloxy)- propyl]; <i>N,N</i> - diorgano		434-240-6	—	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	dithiocarbamate molybdenum complex						
050-023-00	Mixture of: bis[(2-ethyl-1-oxohexyl)oxy]dioctyl stannane; bis[((2-ethyl-1-oxohexyl)oxy)dioctylstannyl]oxide; bis(1-phenyl-1,3-decanedionyl)dioctyl stannane; (2-ethyl-1-oxohexyl)oxy-(1-phenyl-1,3-decanedionyl)dioctyl stannane	422-920-5	—	Xn; R48/22 N; R50-53	Xn; N R: 48/22-50/53 S: (2-)23-36-61	C ≥ 10 %: Xn, N; R48/22-50/53 ≤ C < 10 %: N; R50/53 0,25 % ≤ C < 2,5 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
050-024-00	Mixture of: tri- <i>p</i> -tolyltin hydroxide; hexa- <i>p</i> -tolyl-distannoxane	432-230-6	—	T; R48/25 Xn; R22 Xi; R38-41 R43 N; R50-53	T; N R: 22-38-41-43-48/25-50/53 S: (1/2-)22-26-36/37/39-45-60-61		
064-001-00	Calcium(III)sulfite trihydrate	456-900-25	1285-81	N; R51-53	N R: 51/53 S: 61		
078-011-00	Hydroxydisulfite platinum(II) acid	423-310-1	161420-92	Xn; R22-48/20 C; R35 R42/43 R52-53	C R21/22 22-35-42/43-48/20/21/22-52/53 S: (1/2-)23-24-26-28-36/37/39-45-61		
078-012-00	Platinum(IV) nitrate/nitric acid solution	432-400-1	—	C; R35 N; R50-53	C; N R: 35-50/53 S: (1/2-)26-36/37/39-45-60-61		
082-012-00	Barium calcium cesium lead samarium strontium	431-780-4	199876-46	Xn; R22-48/22 N; R51-53	Xn; N R: 22-48/22-51/53 S: (2-)22-36-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	bromide chloride fluoride iodide europium doped						
601-080-00	Mixture of: <i>sec</i> -butylphenyl(phenyl)methane, mixed isomers; 1-(<i>sec</i> -butylphenyl(phenyl)-2-phenylethane, mixed isomers; 1-(<i>sec</i> -butylphenyl-1-phenylethane, mixed isomers	431-100-6	—		N; R50-53	N R: 50/53 S: 60-61	
601-081-00	cyclohexadeca-1,9-diene	431-730-1	14277-06-9		Xi; R38 R43 R53	Xi R: 38-43-53 S: (2-)36/37-61	
601-082-00	Mixture of: endo-2-methyl-exo-3-methyl-exo-2-[(exo-3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane; exo-2-methyl-exo-3-methyl-endo-2-[(endo-3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane	434-420-4	—		Xi; R38-41 N; R50-53	Xi; N R: 38-41-50/53 S: (2-)23-26-37/39-57-60-61	
601-083-00	endo-hexyl-bicyclo[2.2.1]hept-2-ene	435-000-3	22094-83-1		Xn; R65 Xi; R38 R53	Xn R: 38-65-53	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					S: (2-)37-62-61		
601-084-00	Mixture of: 5-endo-butyl-bicyclo[2.2.1]hept-2-ene; 5-exo-butyl-bicyclo[2.2.1]hept-2-ene (80:20)		435-180-3		Xn; R65 Xi; R38 N; R50-53	Xn; N R: 38-65-50/53 S: (2-)37-62-60-61	
602-105-06	Sodium 1,1,2,2,3,3,4,4,4-nonafluoro-1-butanedisulfinate		422-100-7	102061-8	Xn; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39	
602-106-00	2-bromo-4,6-difluoroaniline		429-430-0	444-14-4	Xn; R22 N; R51-53	Xn; N R: 22-51/53 S: (2-)25-61	
602-107-00	1,3,4,4-tetrafluoro-1-iodo-2-butene		439-500-2	33831-83	Xn; R22 Xi; R38 N; R51-53	Xn; N R: 22-38-51/53 S: (2-)37-61	
602-108-00	2,3,5,6-tetrafluorophenylmethanol		443-840-7	4084-38-2	Xn; R22 Xi; R36 R43	Xn R: 22-36-43 S: (2-)26-36/37	
603-211-00	3-epoxypropyltrimethylammonium chloride ... %; glycidyl trimethylammonium chloride ... %	B E	221-221-0	3033-77-0	Carc. Cat. 2; R45 Muta. Cat. 3; R68 Repr. Cat. 3; R62 Xn; R21/22-48/22 Xi; R41 R43 R52-53	T R: 45-21/22-41-43-48/22-62-68-52/53 S: 53-45-61	
603-212-00	3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyran; galaxolide;		214-946-9	1222-05-5	N; R50-53	N R: 50/53 S: 60-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(HHCB)						
603-213-00-2	methoxy-2-methylbutane; <i>tert</i> -amyl methyl ether	213-611-4994-05-8		F; R11 Xn; R22 R67	F; Xn R: 11-22-67 S: (2-)9-16-23-33		
603-214-00-8	diisopropoxycyclohexane	413-740-81132-95-2		C; R34	C R: 34 S: (1/2-)23-26-36/37/39-45		
603-215-00-3	hydroxy-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)	418-330-2162241-33		E; R2 Xn; R22-48/22 Xi; R41 R43 N; R50-53	E; Xn; N R: 2-22-41-43-48/22-50/53 S: (2-)22-26-36/37/39-60-61		
603-216-00-9	1-amino-2,3-dihydro-1 <i>H</i> -inden-2-ol	422-660-27480-35-5		Xi; R41 R43 R52-53	Xi R: 41-43-52/53 S: (2-)24-26-37/39-61		
603-217-00-4	6- <i>tert</i> -butylphenyl 2-butyl-2-ethyl-1,3-propanediolphosphite	423-560-1161717-32		R43 R53	Xi R: 43-53 S: (2-)24-37/39-61		
603-220-00-0	{benzyl[2-(2-methoxyphenoxy)ethyl]amino}-3-(9 <i>H</i> -carbazol-4-yloxy)propan-2-ol	432-890-572955-94		R53	R: 53 S: 61		
603-221-00-6	2-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing < 0,1 % 4-chloroaniline	433-580-2214353-17		Xn; R22 C; R34 N; R51-53	C; N R: 22-34-51/53 S: (1/2-)26-36/37/39-45-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(EC No 203-401-0)]						
603-221-01-02	E 4-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing ≥ 0,1 % 4-chloroaniline (EC No 203-401-0)]	433-580-2214353-17	433-580-2214353-17	Car. Cat 2; R45 Xn; R22 C; R34 N; R51-53	T; N R: 45-22-34-51/53 S: 53-45-61		
603-222-00-02	[(4-dimethylamino-3-hydroxy-6-methyltetrahydropyran-2-yl)oxy]-2-ethyl-3,4,12-trihydroxy-9-methoxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-1-oxacyclotetradecane	402R, 410R, 418R, 420R, 421R, 435R, 445R, 455R, 465R, 475R, 485R, 495R, 505R, 515R, 525R, 535R, 545R, 555R, 565R, 575R, 585R, 595R, 605R, 615R, 625R, 635R, 645R, 655R, 665R, 675R, 685R, 695R, 705R, 715R, 725R, 735R, 745R, 755R, 765R, 775R, 785R, 795R, 805R, 815R, 825R, 835R, 845R, 855R, 865R, 875R, 885R, 895R, 905R, 915R, 925R, 935R, 945R, 955R, 965R, 975R, 985R, 995R	402R, 410R, 418R, 420R, 421R, 435R, 445R, 455R, 465R, 475R, 485R, 495R, 505R, 515R, 525R, 535R, 545R, 555R, 565R, 575R, 585R, 595R, 605R, 615R, 625R, 635R, 645R, 655R, 665R, 675R, 685R, 695R, 705R, 715R, 725R, 735R, 745R, 755R, 765R, 775R, 785R, 795R, 805R, 815R, 825R, 835R, 845R, 855R, 865R, 875R, 885R, 895R, 905R, 915R, 925R, 935R, 945R, 955R, 965R, 975R, 985R, 995R	Xi; R36	Xi R: 36 S: (2-)26		
603-223-00-07	cyclopentylidene cyclopentanol; 1,1'-bi(cyclopentyliden)-2-ol	434-270-16261-30-9	434-270-16261-30-9	Xi; R38-41 R52-53	Xi R: 38-41-52/53 S: (2-)26-37/39-61		
603-224-00-02	ethoxy-1,1,1,2,3,4,4,5,5,6,6,6-dodecafluoro-2-(trifluoromethyl)-hexane	435-790-1297730-93R53	435-790-1297730-93R53	R53	R: 53 S: 61		
603-225-00-08	Streptomycin A9-oxime (E); (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-((2,6-didesoxy-3-C-methyl-3-O-methyl-α-L-ribohexopiranosyl)oxy)-14-ethyl-7,12,13-	437-070-013127-18-9	437-070-013127-18-9	N; R51-53	N R: 51/53 S: 61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-tridesoxy-3-dimethylamino-β-D-xylohexapiranosyl)oxy)oxacyclotetradecan-2-ona-10-oxime (E)					
603-226-00-3	(4-(4-methoxyphenyl)-1,3,5-triazin-2,4-diyl)bisbenzene-1,3-diol	444-500-01440-00-2	R52-53	R: 52/53 S: 61		
603-227-00-9	ω-[[[(1,1-dimethylethyl)dioxy]carbonyl]oxy]-poly[oxy(methyl-1,2-ethanediyl)] ether with 2,2-bis(hydroxymethyl)-1,3-propanediol (4:1); reaction product of: α-hydro-ω-((chlorocarbonyl)oxy)-poly(oxy(methyl-1,2-ethanediyl)) ether with 2,2-bis(hydroxymethyl)-1,3-propanediol with potassium 1,1-dimethylethylperoxalate	445-060-2203574-04	OR R7 N; R50-53	O; N R: 7-50/53 S: (2-)/3/7-14-36/37/39-60-61		
603-228-00-4	(R*,R*)-6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran;	419-620-1	—	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)/36/37-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	6-fluoro-2-(2-oxiranyl)chromane						
603-229-06 X	Sodium (Z)-3-chloro-3-(4-chlorophenyl)-1-hydroxy-2-propene-1-sulfonate	420-800-7	—	Xi; R38-41 R43 N; R50-53	Xi; N R: 38-41-43-50/53 S: (2-)24-26-37/39-60-61		
603-230-00	2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan	440-030-5	—	Xi; R38-41 R53	Xi R: 38-41-53 S: (2-)26-37/39-61		
603-231-00 (S)	1,1-diphenyl-1,2-propanediol	443-220-6	—	R52-53	R: 52/53 S: 22-61		
603-232-00	2,6,6,8,8,10,10-hexamethyl-9-[1-(4-oxiranylmethoxyphenyl)ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane	444-420-6	—	R53	R: 53 S: 61		
603-233-00	Mixture of: 4-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 4-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 1-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol;	444-430-0	—	N; R51-53	N R: 51/53 S: 61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	1-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-1H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-3H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol						
603-234-001	(R,4R)-4-methoxy-2,2,7,7-tetramethyltricyclo(6.2.1.0(1,6))undec-5-ene	444-480-3	—		Xi; R38 N; R51-53	Xi; N R: 38-51/53 S: (2-)37-61	
604-074-001	tetrabromobisphenol A; 2,2',6,6'-tetrabromo-4,4'-isopropylidenediphenol	201-236-9	979-94-7		N; R50-53	N R: 50/53 S: 60-61	
604-075-006	(1,1,3,3-tetramethylbutyl)phenol; 4-tert-octylphenol	205-426-2	140-66-9		Xi; R38-41 N; R50-53	Xi; N R: 38-41-50/53 S: (2-)26-37/39-60-61 ≤ C < 20 %: Xi, N; R41-50/53 5 % ≤ C < 10 %: Xi, N; R36-50/53 2,5 % ≤ C < 5 %: N; R50/53 0,25 % ≤ C < 2,5 %:	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

							N; R51/53 0,025 % ≤ C < 0,25 %: R52/53
604-076-00-1	phenolphthalein		201-004-777-09-8		Carc. Cat. 2; R45 Muta. Cat. 3; R68 Repr. Cat. 3; R62	T R: 45-62-68 S: 53-45	C ≥ 5 %: T; R45-62-68 1 % ≤ C < 5 %: T; R45-68
604-077-00-7	2-benzotriazol-2-yl-4-methyl-6-(2-methylallyl)phenol		419-750-998809-58		R53	R: 53 S: 61	
604-079-00-8	3,3'-(1,3-phenylene-bis(1-methylethylidene))bis-phenol		428-970-413595-25		Repr. Cat. 3 R62 R43 N; R51-53	Xn; N R: 43-62-51/53 S: (2-)22-36/37-61	
604-080-00-3	fluoro-3-trifluoromethylphenol		432-560-061721-07		Xn; R20 C; R35 R43 N; R51-53	C; N R: 20-35-43-51/53 S: (1/2-)26-28-36/37/39-45-61	
604-081-00-9	bis(4-hydroxyphenyl)-1-phenylethane		433-130-51571-75-1		N; R50-53	N R: 50/53 S: 25-60-61	
604-082-00-4	E chloro-6-fluoro-phenol		433-890-82040-90-6		Muta. Cat. 2 R46 Repr. Cat. 3 R62 Xn; R22 C; R34 R43 N; R51-53	T; N R: 46-22-34-43-62-51/53 S: 53-45-61	
604-083-00-4 X	4,4'-sulfonylbisphenol, polymer with ammonium		439-270-3260408-02		R53	R: 53 S: 61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	chloride(NH ₄ Cl), pentachlorophosphorane and phenol						
604-084-00-5	ethoxy-2,3- difluorobenzene	441-000-4121219-07		Xn; R22 R52-53	Xn R: 22-52/53 S: (2-)23-61		
604-087-00-1	mixture of: 1,2- naphthoquinonediazide-5- sulfonylchloride (or sulfonic acid)monoester with 4,4'-(1- (4-(1-(4- hydroxyphenyl)-1- methylethyl)phenyl)ethylidene)bisphenol; 1,2- naphthoquinonediazide-5- sulfonylchloride (or sulfonic acid)diester with 4,4'-(1- (4-(1-(4- hydroxyphenyl)-1- methylethyl)phenyl)ethylidene)bisphenol; 1,2- naphthoquinonediazide-5- sulfonylchloride (or sulfonic acid)triester with 4,4'-(1- (4-(1-(4- hydroxyphenyl)-1- methylethyl)phenyl)ethylidene)bisphenol	433-640-8—		F; R17 R44 R53	F R: 17-44-53 S: (2-)15-22-61		
604-089-00-2	methyl-5- <i>tert</i> - butylthiophenol	444-970-7—		R10 Repr.Cat.3 R63 Xn; R48/20/22(05) Xi; R36/38 R43	Xn; N R: 10-36/38-43-48/20/22-63-65-67-50/53 S: (05)26-36/37-62-60-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					R67 N; R50-53			
605-037-00-1	trans-3-[2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde; 3-[(E)-2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde	421-800-1120578-03	120578-03		R53	R: 53 S: 22-61		
605-038-00-7	methyl-5-phenylpentan-1-al	433-900-055066-49	55066-49		Xn; R22 Xi; R38 R43 N; R51-53	Xn; N R: 22-38-43-51/53 S: (2-)36/37-61		
605-039-00-2	2-dihydroxy-5-nitrobenzaldehyde	441-810-8116313-85	116313-85		Xn; R22 Xi; R41 R43	Xn R: 22-41-43 S: (2-)22-24-26-37/39		
606-124-00-7	cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)-1,3-propanedione	421-080-7161462-35	7161462-35		Xn; R48/22 N; R50-53	Xn; N R: 48/22-50/53 S: (2-)36-60-61		
606-125-00-2	benzylimidazolidine-2,4-dione	421-340-16777-05-5	6777-05-5		Xn; R22	Xn R: 22 S: (2-)22		
606-126-00-8	bis(2,3-dihydroxypropylamino)anthraquinone	421-470-799788-75	799788-75		N; R51-53	N R: 51/53 S: 61		
606-128-00-2	2'-(1,3-phenylene)bis[5-chloro-1H-isoindole]-1,3(2H)-dione	422-650-8148935-94	8148935-94		R53	R: 53 S: 61		
606-129-00-4	4-amino-[2S-di(methylphenyl)amino]-1,6-diphenyl-4Z-hexen-3-one;	423-090-7156732-13	7156732-13		R53	R: 53 S: 61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(2S,4Z)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one						
606-130-00-X	00-(1,4-dioxaspiro[4.5]dec-8-yl)-cyclohexanone		423-860-256309-94	R43 R52-53	Xi R: 43-52/53 S: (2-)24-37-61		
606-131-00	00-cyclic 3-(1,2-ethanediyloxy)acetale-estra-5(10),9(11)-diene-3,17-dione	E	427-230-85571-36-8	Repr. Cat. 2; R60 Xn; R48/22 N; R51-53	T; N R: 60-48/22-51/53 S: 53-45-61		
606-132-00	00(6)-6,19-epoxyandrost-4-ene-3,17-dione		433-490-36563-83-3	R43 R52-53	Xi R: 43-52/53 S: (2-)24-37-61		
606-134-00	00androsta-1,4,9(11)-triene-3,17-dione		433-560-315375-21	Repr. Cat.3; R62	Xn R: 62 S: (2-)22-36/37		
606-135-00	00cyclohexadecanone		438-930-82550-52-9	R53	R: 53 S: 61		
606-136-00	003,6R,9S,12R,15S,18R,21S,24R,27S,30S,33R,36R,39S,42R,45S,48R,51S,54R,57S,60S,63R,66S,69R,72S,75R,78S,81R,84S,87R,90S,93R,96S,99R,102S,105R,108S,111R,114S,117R,120S,123R,126S,129R,132S,135R,138S,141R,144S,147R,150S,153R,156S,159R,162S,165R,168S,171R,174S,177R,180S,183R,186S,189R,192S,195R,198S,201R,204S,207R,210S,213R,216S,219R,222S,225R,228S,231R,234S,237R,240S,243R,246S,249R,252S,255R,258S,261R,264S,267R,270S,273R,276S,279R,282S,285R,288S,291R,294S,297R,300S,303R,306S,309R,312S,315R,318S,321R,324S,327R,330S,333R,336S,339R,342S,345R,348S,351R,354S,357R,360S,363R,366S,369R,372S,375R,378S,381R,384S,387R,390S,393R,396S,399R,402S,405R,408S,411R,414S,417R,420S,423R,426S,429R,432S,435R,438S,441R,444S,447R,450S,453R,456S,459R,462S,465R,468S,471R,474S,477R,480S,483R,486S,489R,492S,495R,498S,501R,504S,507R,510S,513R,516S,519R,522S,525R,528S,531R,534S,537R,540S,543R,546S,549R,552S,555R,558S,561R,564S,567R,570S,573R,576S,579R,582S,585R,588S,591R,594S,597R,600S,603R,606S,609R,612S,615R,618S,621R,624S,627R,630S,633R,636S,639R,642S,645R,648S,651R,654S,657R,660S,663R,666S,669R,672S,675R,678S,681R,684S,687R,690S,693R,696S,699R,702S,705R,708S,711R,714S,717R,720S,723R,726S,729R,732S,735R,738S,741R,744S,747R,750S,753R,756S,759R,762S,765R,768S,771R,774S,777R,780S,783R,786S,789R,792S,795R,798S,801R,804S,807R,810S,813R,816S,819R,822S,825R,828S,831R,834S,837R,840S,843R,846S,849R,852S,855R,858S,861R,864S,867R,870S,873R,876S,879R,882S,885R,888S,891R,894S,897R,899S,901R,903S,905R,907S,909R,911S,913R,915S,917R,919S,921R,923S,925R,927S,929R,931S,933R,935S,937R,939S,941R,943S,945R,947S,949R,951S,953R,955S,957R,959S,961R,963S,965R,967S,969R,971S,973R,975S,977R,979S,981R,983S,985R,987S,989R,991S,993R,995S,997R,999S		442-230-4735418-704	Xn; R36 R53	Xi R: 36-53 S: (2-)26-61		
606-137-00	00-8ns-7,7'-dimethyl-(4H,4H)- (2,2')bi[benzo[1,4]thiazinylidene]-3,3'-dione		444-750-0211387-26	R53	R: 53 S: 22-61		
606-138-00	0023 butyl-5-nitrobenzofuran-3-yl)[4-(3-dibutylaminopropoxy)phenyl]methanone		444-800-1141645-23	R10 Xn; R22-48/221 Xi; R38-41 R43	Xn; N R: 210-22-38-41-43-48/22-50/53 S: (2-)23-26-30/37/39-60-61 ≤ C <	C ≥ 25 %: 41-43-48/22-50/53 41-43-48/22-50/53 30/37/39-60-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					N; R50-53	25 %: Xn, N; R38-41-43-48/22-50/53 10 % ≤ C < 20 %: Xn, N; R41-43-48/22-50/53 5 % ≤ C < 10 %: Xi, N; R36-43-50/53 2,5 % ≤ C < 5 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
606-139-00	059-4- (3,4- dichlorophenyl)-3,4- dihydro-2H- naphthalen-1- one	444-830-5124379-29	953		R: 53 S: 61		
606-140-00	4- hydroxy-1- (4-(4-(2- hydroxy-2- methylpropionyl)benzyl)phenyl)-2- methylpropan-1- one	444-860-9474510-5	7	Xn; R48/22 N; R50-53	Xn, N R: 48/22-50/53 S: (2-)22-36-60-61		
606-141-00 X	Sodium 3- (methoxycarbonyl)-4- oxo-3,4,5,6- tetrahydro-2- pyridinolate	418-410-7	—	Xi, R36	Xi R: 36 S: (2-)26		
606-142-00	Mixture of: (1RS,2SR,7SR,8SR,E) 9 and	434-290-9	—	Xn; R22 N; R51-53	Xn, N R: 22-51/53 S: (2-)61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	10-ethylidene-3-oxatricyclo[6.2.1.0 ^(2,7)]undecan-4-one; (1 <i>RS</i> ,2 <i>SR</i> ,7 <i>SR</i> ,8 <i>SR</i> , <i>Z</i>)-10-ethylidene-3-oxatricyclo[6.2.1.0 ^(2,7)]undecan-4-one; (1 <i>RS</i> ,2 <i>SR</i> ,7 <i>SR</i> ,8 <i>SR</i> , <i>Z</i>)-9-ethylidene-3-oxatricyclo[6.2.1.0 ^(2,7)]undecan-4-one						
607-580-00 X	ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate	422-360-1	100491-29	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)22-24-37-61		
607-618-00	6-nadione sodium bisulfite; 2-naphthalenesulfonic acid,1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-, sodium salt	204-987-0	130-37-0	Xi; R36/38 N; R50-53	Xi; N R: 36/38-50/53 S: (2-)24/25-60-61		
607-619-00	6-nadione nicotinamide bisulfite; 1,2,3,4-tetrahydro-2-methyl-1,4-dioxonaphthalene-2-sulfonic acid, compound with nicotin-3-amide (1:1)	277-543-7	73581-79	Xi; R36/38 N; R50-53	Xi; N R: 36/38-50/53 S: (2-)24/25-60-61		
607-620-00	sodium nitrilotriacetate	225-768-6	5064-31-3	Carc. Cat. 3; R40 Xn; R22 Xi; R36	Xn R: 22-36-40	C ≥ 25 %: Xn; R22-36-40	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						S: (2-)26-36/37-46	20 ≤ % 25 %: Xn; R36-40 5 ≤ % C < 20 %: Xn; R40	
607-621-00	milbemectin (ISO); [mixture of milbemycin A3 (CAS No 51596-10-2) and milbemycin A4 (CAS No 51596-11-3) (30:70)]	—	—	Xn; R20/22 N; R50-53	Xn; N R: 20/22-50/53 S: (2-)46-60/61	C ≥ 25 %: Xn, N; R20/22-50/53 0,25 % ≤ C < 25 %: N; R50/53 0,025 % ≤ C < 0,25 %: N; R51/53 0,0025 % ≤ C < 0,025 %: R52/53		
607-622-00-7	ethylhexyl-2-ethylhexanoate	231-057-1	7425-14-1	Repr. Cat. 3; R63	Xn R: 63 S: (2-)36/37			
607-623-00-2	diisobutyl phthalate	201-553-2	284-69-5	Repr. Cat. 2; R61 Repr. Cat. 3; R62	T R: 61-62 S: 53-45	C ≥ 25 %: T; R61-62 5 % ≤ C < 25 %: Xn; R62		
607-624-00-8	perfluorooctane sulfonic acid; heptadecafluorooctane sulfonic acid; [1] potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate; [2] diethanolamine perfluorooctane sulfonate; [3]	217-179-8 220-527-1 274-460-8 249-415-0 249-644-6	1763-23-1 1295-39-3 7025-14-8 29081-56-0 29457-72-1	Chf. Cat. R40 R61 R61 T; R48/25 Xn; R20/22 R64 N; R51-53	T; N R: 61-20/22-40-48/25-64-51/53 S: 53-45-61			

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate; [4] lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate [5]						
607-625-0013	dinafop- propargyl (ISO)	—	105512-06	Xn; R22-48/22-51/53 R43 N; R50-53.	Xn; N R: 22-43-48/22-50/53 S: (2-)24-36/37-46-60-61	C ≥ 25 %: R22-43-48/22-50/53 R43-46-60-61 ≤ C < 25 %: Xn, N; R43-48/22-51/53 2,5 % ≤ C < 10 %: Xi, N; R43-51/53 0,25 % ≤ C < 2,5 %: Xi; R43-52/53 0,001 % ≤ C < 0,25 %: Xi; R43	
607-626-0019	1-(2,4- dichlorophenyl)-5- (trichloromethyl)-1H-1,2,4- triazole-3- carboxylate	401-290-5	103112-35	C R45 N; R50-53	T; N R: 45-50/53 S: 53-45-60-61		
607-627-0045	(4S,5S)-4- benzyl-2- oxo-5- oxazolidinyl]methyl 4- nitrobenzenesulfonate	416-360-0	162221-28	R43	Xi R: 43 S: (2-)22-24-37		
607-628-001X	oxo-4- (p- tolyl)butyric acid adduct	419-240-6	171054-89	Xn; R41	Xi R: 41 S: (2-)26-39		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	with 4-ethylmorpholine						
607-629-00-2	[2-methyl-1-(1-oxopropoxy)propoxy] (4-phenylbutyl)phosphiny] acetic acid	419-270-1123599-8226		Xn; R36	Xi R: 36 S: (2-)26		
607-630-00-6	acrylic acid, 3-(trimethoxysilyl)propyl ester	419-560-64369-14-6		Xn; R20 C; R34 R43 R52-53	C R: 20-34-43-52/53 S: (1/2-)26-36/37/39-45-61		
607-631-00-6	mixture of: 2-(2-((oxo(phenyl)acetyl)oxy)ethoxy)ethyl oxo(phenyl)acetate; (2-(2-hydroxyethoxy)ethyl) oxo(phenyl)acetate	442-300-8—		R43	Xi R: 43 S: (2-)24-37		
607-632-00-1	[3-(2,4-di-(1,1-dimethylpropyl)phenoxy)-propyl]-1-hydroxy-5-(2-methylpropyl-oxycarbonylamino)-naphthamide	420-210-1111244-14		R53	R: 53 S: 61		
607-633-00-7	sodium 5-{[4-chloro-6-(1-naphthylamino)-1,3,5-triazin-2-yl]amino}-4-hydroxy-3-[(E)-(4-methoxy-2-sulfonatophenyl)diazenyl]-2,7-naphthalenedisulfonate	440-480-2341026-59		Xn; R41 R43	Xi R: 41-43 S: (2-)22-24-26-37/39		
607-634-00-2	(-)-2-acetoxypropionylchloride; (1S)-2-chloro-1-	420-610-436394-75		Xn; R22 C; R34 R43	C R: 22-34-43 S: (1/2-)23-26-36/37/39-45		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	methyl-2-oxoethyl acetate						
607-635-00-8	Sodium N-(3-propionato)-L-aspartate	422-090-4172737-80			Xn; R41	Xi R: 41 S: (2-)26-39	
607-636-00-3	bromo-2-methylpropyl propionate	422-900-6158894-67			R10 Carc.Cat.3 R40 C; R34 R43	C R: 10-34-40-43 S: (1/2-)7/9-8-23-26-36/37/39-45	
607-637-00-9	Sodium 8-amino-5-{4-[2-(sulfonatoethoxy)sulfonyl]phenylazo} naphthalene-2-sulfonate	423-730-5250688-43			Xn; R41	Xi R: 41 S: (2-)26-39	
607-638-00-4	hydroxybenzoic acid 2-butyloctyl ester	431-090-3190085-41			R53	R: 53 S: 61	
607-639-00-X	(2-oxo-5-(1,1,3,3-tetramethylbutyl)-2,3-dihydro-1-benzofuran-3-yl)-4-(1,1,3,3-tetramethylbutyl)phenyl acetate	431-770-1216698-07			R53	R: 53 S: 61	
607-641-00-0	(formylamino)-3-thiophenecarboxylic acid; 2-formamido-3-thiophenecarboxylic acid	431-930-943028-69			Xn; R22 R43	Xn R: 22-43 S: (2-)22-24-37	
607-642-00-6	6,9-trithiaundecamethylene-1,11-dimethacrylate	432-210-7141631-22			R53 R50-53	N R: 50/53 S: 60-61	
607-643-00-1	dimethyl (2S)-2-hydroxysuccinate	432-310-0617-55-0			R10 Xi; R41 R43	Xi R: 10-41-43	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						S: (2-)24-26-37/39-43		
607-644-00-7	1,1-dimethyl-2,2-dimethyl-6-methylenecyclohexanecarboxylate	432-350-981752-87			Xi; R38	Xi R: 38 S: (2-)37		
607-645-00-2	2-(4-fluoro-6-(methyl-(2-(sulfatoethylsulfonyl)ethyl)amino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-methyl-2-sulfonatophenylazo)naphthalene-1,7-disulfonate	432-550-6243858-01			Xi; R41	Xi R: 41 S: (2-)22-26-39		
607-646-00-8	erythro-hexanoic acid 2,4-dideoxy-3,5-O-(1-methylethylidene)-1,1-dimethylethylester; tert-butyl 2-[(4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate	432-960-5124655-09			Xn; R22	Xn R: 22 S: (2-)25		
607-647-00-3	acetoxymethyl-2-(R,S)butyryloxymethyl-1,3-oxathiolane	433-530-1143446-73			Xn; R22 R43 N; R50	Xn; N R: 22-43-50 S: (2-)24-37-57-61		
607-649-00-3	(chlorocarbonyl)-2-methylphenyl]acetate	433-690-0167678-46			C R35 R43	C R: 35-43 S: (1/2-)7/8-26-36/37/39-45		
607-650-00-X	methyl-1,5-pentanediamine-1,3-benzenedicarboxylate	433-910-5145153-52			R23	Xi R: 43 S: (2-)24-37		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

607-651-00	Sodium 2- (nonanoyloxy)benzenesulfonate	434-360-991125-43	Xi; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39		
607-652-00	Ethyl N ² - dodecanoyl- L- argininate hydrochloride	434-630-660372-77	Xi; R41 N; R50	Xi; N R: 41-50 S: (2-)26-39-61		
607-653-00	Crakis(bis(2- hydroxyethyl)methylammonium) 3-(4-(7- acetylamino-1- hydroxy-3- sulfonatophthalen-2- ylazo)-5- methoxy-2- sulfonatophenylazo)-7- (4- amino-3- sulfonatophenylamino)-4- hydroxynaphthalene-2- sulfonate	434-840-8225786-91	N R51-53	N R: 51/53 S: 61		
607-654-00	(S)-3- hydroxy- γ- butyrolactone	434-990-47331-52-4	R43	Xi R: 43 S: (2-)23-24-37		
607-655-00	Ethyl 6,8- dichlorooctanoate	435-080-11070-64-0	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
607-656-00	Sodium salt of 4- amino-3,6- bis[[5- [[4- chloro-6- [(2- methyl-4- sulfophenyl)amino]-1,3,5- triazin-2- yl]amino]-2- sulfophenyl]azo]-5- hydroxy-2,7- naphthalenedisulfonic acid	435-350-7141250-43	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61		
607-657-00	Potassium 7-(4-(4-	436-920-8172399-10	Xi; R41	Xi R: 41		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(3-(2-sulfatoethanesulfonyl)phenylamino)-6-(4-(2-sulfatoethanesulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate				S: (2-)22-26-39		
607-658-00-30	di-amino-6,13-dichloro-2-((6-(((4-(1,1-dimethylethyl)phenyl)sulfonyl)amino)-2-naphthalenyl)sulfonyl)-4,11-triphenodioxazinedisulfonic acid, lithium potassium sodium salt	440-770-9371921-630		Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)26-39-61		
607-659-00-09	potassium N-[5-[[4-[[3-[(aminocarbonyl)amino]-4-[(3,6,8-trisulfonatonaphthalen-2-yl)azo]phenyl]amino]-6-chloro-1,3,5-triazin-2-yl]amino]-2-sulfonato-4-[[4-[-2-(oxysulfonato)ethyl]sulfonyl]phenyl]azo]phenyl]-3-aminopropanoic acid	442-030-0321912-474		Xi; R41	Xi R: 41 S: (2-)22-26-39		
607-660-00-44	[4-[4-fluoro-6-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino]phenylazo]phenylazo}naphthalene-4,6,8-trisulfonate, trisodium salt	442-230-8321679-523		Xi; R41	Xi R: 41 S: (2-)22-26-39		
607-661-00-1- X	dimethylethyl 4'-	442-850-9114772-4064		R43 R53	Xi R: 43-53 S: (2-)22-24-37-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(bromomethyl)biphenyl-2-carboxylate					
607-662-00	1-methyl-2-(acetylamino)-3-chloropropionate	442-860-3	87333-22	R43 N; R50-53	Xi; N R: 43-50/53 S: (2-)24-37-60-61	
607-663-00	1-(2-ethylhexyl)naphthalene-2,6-dicarboxylate	442-980-6	127474-9	R53	R: 53 S: 61	
607-664-00	1-methyl-2-chlorosulfonyl-4-(methanesulfonylamino)methyl)benzoate	443-120-2	393509-7	Xi; R41 N; R51-53	Xi; N R: 41-51/53 S: (2-)26-39-61	
607-665-00	trans-1-methyl-2-ethylbut-2-enoate	443-150-6	101226-8	R10	R: 10 S: 23	
607-666-00	2-(5-(benzyloxy)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxopentanoic acid	443-560-5	88784-33	Xi; R36	Xi R: 36 S: (2-)26	
607-667-00	1-chloro-1-ethylcyclohexyl carbonate	444-950-8	99464-83	Muta.Cat. R68 R43	Xn R: 43-68 S: (2-)23-36/37	
607-668-00	trans-2-isopropyl-5-carboxy-1,3-dioxane	445-770-2	42031-28	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61	
607-669-00	1-methyl (9-acetoxy-3,8,10-triethyl-7,8,10-trimethyl-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl)octadecanoate	445-990-9	376588-1	R43 R53	Xi R: 43-53 S: (2-)24-37-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

607-670-00	Diethyl-3-(4-(5-ammonio-2-butyl)benzofuran-3-yl)carbonylphenoxy)propyl ammonium oxalate; (5-amino-2-butylbenzofuran-3-yl) [4-(3-dibutylaminopropoxy)phenyl]methanone, dioxalate	448-700-9	500791-70	Xn; R48/22 Xi; R41 R43 N; R50-53	Xn; N R: 41-43-48/22-50/53 S: (2-)22-26-30/37/39-60-61	C ≥ 10 %: R41-43-48/22-50/53 R41-43-48/22-50/53 < 10 %: Xi, N; R36-43-50/53 2,5 % ≤ C < 5 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
607-671-00	Diethyl 1,4-cyclohexanedicarboxylate	417-310-0	72903-27	N; R51-53	N R: 51/53 S: 61		
607-672-00 X	Mixture of: 2-hydroxy-3-(methacryloyloxy)propyl (2-benzoyl)benzoate; 1-hydroxymethyl-2-(methacryloyloxy)ethyl (2-benzoyl)benzoate; x-hydroxy-y-(methacryloyloxy)propyl(or-ethyl) (2-benzoyl)benzoate	419-000-0	—	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
607-673-00	5-ethyl-5,6,7,8-tetrahydroquinolinium tosylate	419-570-0	—	Xn; R22 R52-53	Xn R: 22-52/53 S: (2-)61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

607-674-00-00	Branches of C ₁₀ -alkyl benzoates	421-090-1	131298-44	Xn; R20	Xn R: 20 S: (2-)23		
607-675-00-00	Mixture of: <i>cis</i> -9-octadecenedioic acid; <i>cis</i> -9- <i>cis</i> -12-octadecadienedioic acid; hexadecanedioic acid; octadecanedioic acid	422-260-8	—	Xi; R41 N; R50-53	Xi; N R: 41-50/53 S: (2-)26-39-60-61		
607-676-00-00	Mixture of: 2-methylnonanedioic acid; 2,4-dimethyl-4-methoxycarbonylundecanedioic acid; 2,4,6-trimethyl-4,6-dimethoxycarbonyltridecanedioic acid; 8,9-dimethyl-8,9-dimethoxycarbonylhexadecanedioic acid	423-670-1	—	Xi; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39		
607-677-00-00	5-dioxopyrrolidin-1-yl <i>N</i> -{[methyl][2-(1-methylethyl)-4-thiazolyl]methyl}amino]carbonyl}-L-valinate	424-660-8	—	Xn; R48/22 Xi; R41 R43	Xn R: 41-43-48/22 S: (2-)22-26-36/37/39		
607-678-00-00	Mixture of: ethyl (2 <i>R</i> ,3 <i>R</i>)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate; ethyl (2 <i>S</i> ,3 <i>S</i>)-3-isopropylbicyclo[2.2.1]hept-5-	427-090-8	—	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)23-25-36/37-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	ene-2-carboxylate					
607-679-00	Mixture of: 3-{5-[3-(4-{1,6-dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(methyl)ammonium di(acetate); 3-{5-[4-(3-{1,6-dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate); 3-{5-[3-(4-{1-[3-(dimethylammonio)propyl]-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate)	431-440-5	—	Xi; R41 N; R51-53	Xi; N R: 41-51/53 S: (2-)22-26-39-61	
607-680-00	2-butyl(6-{2-	432-810-9	—	R53	R: 53 S: 61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}; (4 <i>S</i> ,6 <i>S</i>)-2,2-dimethyl[1,3]dioxan-4-yl)acetate					
607-681-00	Mixture of: 9-nonyl-10-octyl-19-carboxyhexadecylnonadecanoic acid; 9-nonyl-10-octyl-19-carboxyoctadecylnonadecanoic acid; dihexadecyl 9-nonyl-10-octylnonadecandioate; 1-octadecyl,19-hexadecyl 9-nonyl-10-octylnonadecandioate; dioctadecyl 9-nonyl-10-octylnonadecandioate	432-910-2	—	R53	R: 53 S: 61	
607-682-00	Complex mixture of Chinese gum rosin post reacted with acrylic acid	434-230-1	144413-22	R53	R: 53 S: 61	
607-683-00 X	Mixture of: methyl 3-((1 <i>E</i>)-2-methylprop-1-	435-450-0	—	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	enyl)-2,2-dimethylcyclopropanecarboxylate; methyl 3-((1Z)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate (20:80)					
607-684-00	alkenes, C ₁₂₋₁₄ , hydroformylation products, distn. residues, C-(hydrogen sulfobutanedioates), disodium salts	435-660-2243662-6	Xi; R38 R43	Xi R: 38-43 S: (2-)24-37		
607-685-00	ammonium 2-cocoyloxyethanesulfonate	441-050-7	Xi; R38-41	Xi R: 38-41 S: (2-)26-37/39		
607-686-00	6,6'-bis(diazo-5,5',6,6'-tetrahydro-5,5'-dioxo) [methylene-bis(5-(6-diazo-5,6-dihydro-5-oxo-1-naphthylsulphonyloxy)-6-methyl-2-phenylene)]di(naphthalene-1-sulfonate)	441-550-5	E; R2 F; R11 Carc. Cat. 3; R40	E; Xn R: 2-11-40 S: (2-)7-22-36/37		
607-687-00	mixture of: 2-{3,6-bis-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3,6-bis-[(2,3-dimethylphenyl)-	442-800-6	Xi; R38 N; R51-53	Xi; N R: 38-51/53 S: (2-)37-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

<p>methylamino]- xanthylum-9- yl}- benzenesulfonate (2-10 %); 2-{3,6- bis- [(2,4- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (2-10 %); 2-{3,6- bis- [(2,5- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (2-10 %); 2-{3- [(2,3- dimethylphenyl)- methylamino]-6- [(2- ethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,4- dimethylphenyl)- methylamino]-6- [(2- ethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,5- dimethylphenyl)- methylamino]-6- [(2- ethylphenyl)- methylamino]- xanthylum-9-</p>						
---	--	--	--	--	--	--

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	yl}- benzenesulfonate (7-20 %); 2-{3- [(2,3- dimethylphenyl)- methylamino]-6- [(2,4- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,3- dimethylphenyl)- methylamino]-6- [(2,5- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,4- dimethylphenyl)- methylamino]-6- [(2,5- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %)					
607-688-00	(R)-1- cyclohexa-1,4- dienyl-1- methoxycarbonyl- methylammoniumchloride	444-320-2	—	Xn; R22	Xn R: 22 S: (2-)	
607-689-00	Mixture of: methyl 1,4- dimethylcyclohexanecarboxylate (‘para- isomer’ including <i>cis</i> - and <i>trans</i> - isomers);	444-920-4	—	R52-53	R: 52/53 S: 61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	methyl 1,3- dimethylcyclohexanecarboxylate (‘meta- isomer’ including <i>cis</i> - and <i>trans</i> - isomers)						
607-690-00	Diethyl[2 <i>S</i> ,2 <i>S</i>]-6,6,6',6'- tetramethoxy-2,2'- [<i>N,N'</i> - bis(trifluoroacetyl)- <i>S,S</i> '-bi(<i>L</i> - homocysteinyloxy)- <i>S,S</i> diimino]dihexanoate	432-860-1	255387-4	6033			Xi R: 43 S: (2-)24-37
607-691-00	Magnesium salts, fatty acids, C ₁₆₋₁₈ and C ₁₈ unsaturated, branched and linear	448-690-6	—	R53			R: 53 S: 61
607-692-00	Calcium salts, fatty acids, C ₁₆₋₁₈ and C ₁₈ unsaturated, branched and linear	446-470-4	—	R53			R: 53 S: 61
607-693-00	Diethyl 2-(1- (diethylaminohydroxyphenyl)methanoyl)benzoate	443-860-6	302776-6	R53			R: 53 S: 61
607-694-00 X	Diethyl 5,5- diphenyl-2- isoxazoline-3- carboxylate	443-870-0	163520-3	Xn; R22 R43 N; R50-53			Xn; N R: 22-43-50/53 S: (2-)22-36/37-60-61
608-042-00	Diethyl-2,2- diphenyl-2- (3-	421-810-4	194602-2	Xn; R22 Xi; R41 R43			Xn; N R: 22-41-43-51/53

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	pyrrolidinyl)acetonitrile hydrobromide			N; R51-53	S: (2-)24-26-37/39-61		
608-059-06-X	6-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile	421-240-6120068-79		N; R51-53	N R: 51/53 S: 22-61		
608-060-06-5	5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile	421-300-1138564-59		N; R50-53	N R: 50/53 S: 22-60-61		
608-062-00-6	6-fluoro-4-hydroxybenzonitrile	422-810-782380-18		Xn; R22 Xi; R41 N; R51-53	Xn; N R: 22-41-51/53 S: (2-)22-26-39-61		
608-063-00-5	5- α -hydroxy-3-phenoxybenzeneacetonitrile	441-070-661826-76		T; R25 Xi; R41 R43 N; R50-53	T; N R: 25-41-43-50/53 S: (1/2-)9-26-36/37/39-45-60-61		
608-064-00-7	7-anomethyltrimethylsilyl-1,2,3-trimethylsulfurane	433-720-12		R52-53	R: 52/53 S: 61		
609-069-00-7	7-ask ketone; 3,5-dinitro-2,6-dimethyl-4-tert-butylacetophenone; 4'-tert-butyl-2',6'-dimethyl-3',5'-dinitroacetophenone	201-328-981-14-1		Carc. Cat. 3; R40 N; R50-53	Xn; N R: 40-50/53 S: (2-)36/37-46-60-61		
611-154-00-9	9-sodium 5-benzamido-4-hydroxy-3-(4-methyl-2-sulfonatophenylazo)naphthalene-2,7-disulfonate	403-670-692408-46		R52-53	R: 52/53 S: 61		
611-155-00-4	4-oxybis(benzenesulfonylazide)	431-850-47456-68-0		E; R3 F; R11 Xn; R48/22	E; Xn; N R: 3-11-48/22-50/53		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					N; R50-53	S: (2-)14-22-33-35-36-60-61		
611-156-00 X	00 4-ammonium [4- [7-(4- carboxylatoanilino)-1- hydroxy-3- sulfonato-2- naphthylazo]-2,5- dimethoxyphenylazo]benzoate	432-270-4221354-37			Repr. Cat. 3; R62 Xn; R48/22 N; R51-53	Xn; N R: 48/22-62-51/53 S: (2-)36/37-61		
611-157-00	00 benzenesulfonic acid, 3,3'- (methylenebis((dihydroxyphenylene)azo))bis-, potassium sodium salt; potassium sodium 3-[(E)- (6-{3,4- dihydroxy-2- [(Z)-(3- sulfonatophenyl)diazenyl]benzyl}-2,3- dihydroxyphenyl)diazenyl]benzenesulfonate	432-590-4243869-48			Xn; R36 R52-53	Xi R: 36-52/53 S: (2-)26-61		
611-158-00	00 reaction mixture of: 2,3,4,2',3',4'- hexahydroxy-5,5'- diacetyl- diphenylmethane and 6- diazot-5,6- dihydro-5- oxo-1- naphthalenesulfonylchloride and 3- diazot-3,4- dihydro-6- methoxy-4- oxo-1- naphthalenesulfonylchloride	421-520-8			F; R11 R53	F R: 11-53 S: (2-)3-12-16-33-61		
611-159-00	00 sodium 4- amino-6- ((4-((4- (2,4- diaminophenyl)azo)phenylsulfamoyl)phenyl)azo)-5- hydroxy-3- ((4-	421-880-6			Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)26-39-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	nitrophenyl)azo)naphthalene-2,7-disulfonate					
611-160-00	<p>mixture of:</p> <p>1,1,1-tris(phenyl-4'-(3''-diazoo-3'',4''-dihydro-4''-oxo-naphthalene-1''-sulfonato)ethane;</p> <p>1,1,1-tris(phenyl-4'-(6''-diazoo-5'',6''-dihydro-5''-oxo-naphthalene-1''-sulfonato)ethane;</p> <p>reaction product of 1,1,1-tris(<i>p</i>-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (2:1);</p> <p>reaction product of 1,1,1-tris(<i>p</i>-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (1:2)</p>	422-760-6		F; R11 R53	F R: 11-53 S: (2-)3-12-33-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

611-161-00-7	Sodium [1,2'- (2-(8- amino-3,5- disulfonatonaphthalene)azo)- (4'- nitrobenzene)diolato- <i>O,O,N</i>] [(<i>Z</i>)-2,2- ((phenylcarbamoylprop-1'- enyl)azo)-5- sulfamoylbenzene)diolato- <i>O,O,N</i>]chromate(III)	423-100-1	—	Xi; R41	Xi R: 41 S: (2-)26-39		
611-162-00-2	2,2- bis(((2- (dimethylammonio)ethyloxy)carbonyl)phenyl-2- ylazo)benzene-1,3- diolbis(methanesulfonate)	429-600-4	—	Xn; R22 Xi; R41 R51-53	Xn; N R: 22-41-51/53 S: (2-)22-26-39-61		
611-163-00-8	2,2- bis(((2- (dimethylammonio)ethyloxy)carbonyl)phenyl-2- ylazo)benzene-1,3- diol sulfate	429-610-9	—	Xn; R22 Xi; R41 R51-53	Xn; N R: 22-41-51/53 S: (2-)22-26-39-61		
611-164-00-3	Mixture of: 2,2'- dimethyl-2,2'- azobutanenitrile; 2- methylpentanenitrile-2- azo-2'- (2'- methylpropanenitrile); 2,2'- dimethyl-2,2'- azoheptanenitrile; 2- methylheptanenitrile-2- azo-2'- (2'- methylpropanenitrile); 2- methylheptanenitrile-2- azo-2'- (2'- methylbutanenitrile)	429-710-2	—	R10 R32 R44 Xn; R22 N; R51-53	Xn; N R: 10-22-32-44-51/53 S: (2-)12-15-16-47-51-61		
611-165-00-9	Mixture of: tetrasodium 4- amino-6- (5-(2,6-	431-830-5	—	R52-53	R: 52/53 S: 61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	<p>difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate; tetrasodium 4-amino-6-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate</p>					
611-166-00	<p>Mixture of: pentasodium 4-amino-5-hydroxy-3-{{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}}-6-{{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}}naphthalene-2,7-disulfonate; tetrasodium 4-amino-5-hydroxy-3-{{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}}-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium 4-amino-5-hydroxy-6-{{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}}-3-[(E)-4-</p>	432-100-9	—	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)26-39-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate					
611-167-00 X	Sodium bis[tris(2-hydroxyethyl)ammonium] [6-anilino-4'-(4,8-disulfonato-2-naphthylazo)-5'-methyl-3-sulfonato]naphthalene-2-azobenzene-1,2'-diolato]cuprate(II)	435-240-9	—	R52-53	R: 52/53 S: 61	
611-168-00	Mixture of: 3-[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-5-[[4-chloro-6-[[8-hydroxy-3,6-disulfo-7-[(2-sulfophenyl)azo]-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid; 3,5-bis[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid	435-440-6	—	Xi; R41	Xi R: 41 S: (2-)22-26-39	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

611-169-00	Sodium 5-(2- carboxyphenylazo)-6- hydroxynaphthalene-2- sulfonate	435-800-2	—	R52-53	R: 52/53 S: 61		
611-170-00	Mixture of: trisodium 2-((1-(2- hydroxy- κ-O-5- (2- sulfonatoethansulfonyl)phenylazo- κ-N ²)-1- phenylmethyl)azo- κ-N ¹)-4- sulfonatobenzoate(5-)- κ-O)cuprate(II); disodium 2-((1-(5- ethenesulfonyl-2- hydroxy- κ-O- phenylazo- κ-N ²)-1- phenylmethyl)azo- κ-N ¹)-4- sulfonatobenzoate- κ-O- (5-))cuprate(II)	435-880-9	—	R52-53	R: 52/53 S: 22-61		
611-171-00	Mixture of: trisodium 3-(5- (2,6- difluoropyrimidin-4- ylamino)-2- sulfonatophenylazo)-5- (4- fluoro-6- morpholin-4- yl-1,3,5- triazin-2- ylamino)-4- hydroxy-2,7- naphthalenedisulfonate; trisodium 3-(5- (4,6- difluoropyrimidin-2- ylamino)-2-	436-890-6	—	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate					
611-172-00	Mixture of: triammonium 6-amino-3-((2,5-diethoxy-4-(3-phosphonophenyl)azo)phenyl)azo-4-hydroxy-2-naphthalenesulfonate; diammonium 3-((4-((7-amino-1-hydroxy-3-sulfonaphthalen-2-yl)azo)-2,5-diethoxyphenyl)azo)benzoate	438-310-7	—	E; R2 Repr. Cat. 3; R62 Xn; R22-48/22 R52-53	E; Xn R: 2-22-48/22-62-52/53 S: (2-)22-35-36/37-61	
611-173-00	Mixture of: 3-[3-carbamoyl-5-(5-{4-chloro-6-[4-(2-sulfonatooxyethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propanoic acid, trisodium salt; 3-[3-carbamoyl-5-(5-{4-chloro-6-[4-	440-510-4	—	Xi; R41 R43	Xi R: 41-43 S: (2-)22-26-36/37/39	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propanoic acid, disodium salt					
611-174-00	Mixture of: 3-[5-(4-ethenesulfonylbutyrylamino)-2-sulfophenylazo]-5-{4-chloro-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino)-1,3,5-triazin-2-ylamino]-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt; 3-[5-(4-(2-chloroethanesulfonyl)butyrylamino)-2-sulfophenylazo]-5-{4-chloro-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino)-1,3,5-triazin-2-ylamino]-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt	442-290-5457624-86	Xi, R41	Xi R: 41 S: (2-)22-26-39		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

611-175-00	Mixture of: trisodium 5-{4-chloro-6-[N-ethyl-(3-(2-sulfonatooxy)ethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; trisodium 5-{4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; disodium 5-{4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[(4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium 5-{4-chloro-6-[N-ethyl-3-(2-(sulfonatooxy)ethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2,7-disulfonate	444-050-5	—	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61		
------------	--	-----------	---	-------------------	---	--	--

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

611-176-00	2,0-bis(2,3,4-trihydroxybenzyl)- <i>p</i> -cresol ester with 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonate	444-250-2	—	E; R2 F; R11 N; R51-53	E; N R: 2-11-51/53 S: (2-)22-61		
611-177-00	Mixture of: pentasodium bis[6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); tetrasodium [6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato] [6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); trisodium bis[6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III)	444-290-05	0508202-43	Xi; R41 R43 R52-53	Xi R: 41-43-52/53 S: (2-)22-24-26-37/39-61		
611-178-00 X	Mixture of: pentasodium 4-amino-5-hydroxy-3-[(<i>E</i>)-4-[2-(sulfonatoxy)ethylsulfonyl]phenylazo]-6-[(<i>E</i>)-2-sulfonato-4-[2-(sulfonatoxy)ethylsulfonyl]phenylazo]naphthalene-2,7-disulfonate;	445-280-9	—	Xi; R41 R43 R52-53	Xi R: 41-43-52/53 S: (2-)24-26-37/39-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

tetrasodium 4- amino-5- hydroxy-3- {(E)-4- [2- (sulfonatooxy)ethylsulfonyl]phenylazo}-6- [(E)-2- sulfonato-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; tetrasodium 4- amino-5- hydroxy-6- [(E)-2- sulfonato-4- [2- (sulfonatooxy)ethylsulfonyl]phenylazo}-3- [(E)-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; trisodium 4- amino-5- hydroxy-3- [(E)-4- (vinylsulfonyl)phenylazo]-6- [(E)-2- sulfonato-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; trisodium 4- amino-5- hydroxy-3- [(2- hydroxyethylsulfonyl)- phenylazo]-6- [(E)-2- sulfonato-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; trisodium 4- amino-5- hydroxy-3- [(E)-4- (vinylsulfonyl)phenylazo]-6- [-2- sulfonato-4- (2-						
---	--	--	--	--	--	--

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	hydroxyethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate					
611-179-00	<p>Mixture of: pentasodium 2-[[8-[[4-chloro-6-[[4-(2-sulfonatoethylsulfonyl)]phenyl]amino]-1,3,5-triazin-2-yl]amino]-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate; 2-[[8-[[4-chloro-6-[[4-[[2-ethenyl]sulfonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate</p>	450-010-8	—	Xi; R41 R43	Xi R: 41-43 S: (2-)22-24-26-37/39	
611-180-00	<p>On, complexes with diazotised 4-aminobenzenesulfonamide, diazotised 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide, diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol,</p>	417-850-7	—	N; R51-53	N R: 51/53 S: 22-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	sodium salts						
612-238-0038	chloro-2-hydroxypropyl trimethylammonium chloride ... %	B	222-048-33327-22-8		Carc. Cat. 3, R40 R52-53	Xn R: 40-52/53 S: 36/37-61	
612-239-0013	phenyl-3,3',4,4'-tetrayltetraamine; diaminobenzidine		202-110-691-95-2		Carc. Cat. 2; R45 Muta. Cat. 3; R68	T R: 45-68 S: 53-45	
612-240-0019	primethanil (ISO); N-(4,6-dimethylpyrimidin-2-yl)aniline		—	53112-28-0	N; R51-53	N R: 51/53 S: 61	
612-241-0014	piperazine hydrochloride; [1] piperazine dihydrochloride; [2] piperazine phosphate [3]		228-042-76094-40-2 205-551-212-64-3 217-775-81951-97-9	1094-40-2 121-64-3 102-63	Repr. Cat. 3; R62-63 Xi; R36/38 R42/43 R52-53	Xn R: 36/38-42/43-62-63-52/53 S: (1/2-)22-36/37-45-63-61	
612-242-0015 X	pyroprodinil (ISO); 4-cyclopropyl-6-methyl-N-phenylpyrimidin-2-amine		—	121552-61-2	R23 N; R50-53	Xi; N R: 43-50/53 S: (2-)24-37-40-60-61 C ≥ 2,5 %: Xi, N; R43-50/53 40-60-61 < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
612-243-0015	(cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine 2-		420-560-379617-97		Xi; R41 N; R50-53	Xi; N R: 41-50/53 S: (2-)26-39-60-61 C ≥ 10 %: Xi, N; R41-50/53 60-61 < 10 %: Xi, N; R36-50/53	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	hydroxy-2-phenylacetate					2,5 % ≤ C < 5 %: N; R50/53 0,25 % ≤ C < 2, 5 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
612-244-00-0	(piperazin-1-yl)-benzo[d]isothiazole hydrochloride	421-310-687691-88		Repr. Cat. 3; R62 Xn; R22 Xi; R36 R43 N; R50-53	Xn; N R: 22-36-43-62-50/53 S: (2-)22-26-36/37/39-60-61		
612-245-00-6	ethylphenylhydrazine hydrochloride	421-460-219398-06		Carc. Cat. 3; R40 T; R48/25 Xn; R22 Xi; R41 R43 N; R50-53	T; N R: 22-40-41-43-48/25-50/53 S: (1/2-)22-26-36/37/39-45-60-61	C ≥ 25 %: R22-40-41-43-48/25-50/53 R40-41-43-48/25-50/53 5 % ≤ C < 10 %: Xn, N; R36-40-43-48/22-50/53 2,5 % ≤ C < 5 %: Xn, N; R40-43-48/22-50/53 1 % ≤ C < 2,5 %: Xn, N; R40-43-48/22-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
612-246-00-21	E chloroethyl)	429-740-640722-80		Carc. Cat. 2; R45	T		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(3-hydroxypropyl)ammonium chloride				Muta. Cat. 2; R46 Xn; R48/22 R43 R52-53	R: 45-46-43-48/22-52/53 S: 53-45-61		
612-247-00-73-	(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-hydroxy-4-nitrobenzenecarboximidamide	423-530-8	152828-2314		T R: R48/25 Xn; R22 R52-53	T R: 22-48/25-52/53 S: (1/2-)22-36-45-61		
612-248-00-02-	Reaction product of diphenylamine, phenothiazine, and alkenes, branched (C ₈₋₁₀ , C ₉ -rich)	439-540-0	—		Xi; R38 R43 R53	Xi R: 38-43-53 S: (2-)24-37-61		
612-249-00-83-	(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1,2-benzenediamine dihydrochloride	425-030-5	159939-852		Repr. Cat. 3; R62 Xn; R22 C; R34 R43 N; R51-53	C; N R: 22-34-43-62-51/53 S: (1/2-)22-26-36/37/39-45-61		
612-250-00-03-	bromo-N,N-dimethylformiminium chloride	425-970-6	3724-43-4		R14 Repr. Cat. 2; R61 Xn; R22 C; R35	T; C R: 61-14-22-35 S: 53-45		
612-251-00-09-	(1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride	426-020-3	51229-78-8		F; R11 Repr. Cat. 3; R63 Xn; R22 Xi; R38 R43 N; R51-53	F; Xn; N R: 11-22-38-43-63-51/53 S: (2-)7-22-33-36/37-61		
612-252-00-01-	imidacloprid (ISO);	428-040-8	138261-4		Xn; R22	Xn; N		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine				N; R50-53	R: 22-50/53 S: (2-)22-57-60-61		
612-253-00-X	0-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing < 0,5 % formamide (EC No 200-842-0)]	429-400-7	199327-6	1R52-53	R: R52/53 S: 61			
612-253-01-7	7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing ≥ 0,5 % formamide (EC No 200-842-0)]	429-400-7	199327-6	1R2pr. Cat. 2; R61 R52-53	T R: 61-52/53 S: 53-45-61			
612-254-00-0	Reaction products of diisopropanolamine with formaldehyde (1:4)	432-440-8	220444-7	3Carc. Cat. 3; R40 Xn; R22 C; R34 R43 N; R51-53	C; N R: 22-34-40-43-51/53 S: (1/2-)13-25-26-36/37/39-45-61			
612-255-00-03	3-methoxypropyl)-4-piperidinamine	431-950-8	179474-7	9Xn; R21/22 C; R34 R52-53	C R: 21/22-34-52/53 S: (1/2-)26-36/37/39-45-61			
612-256-00-06	benzyl(S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyrate	427-470-3	137864-2	2Xn; R22 R43	Xn R: 22-43 S: (2-)36/37			
612-257-00-01	propylammonium dihydrogenphosphate	433-700-3	35687-90	2Xn; R22	Xn R: 22			

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					S: (2-)22	
612-259-00-2	ethyl-3-trimethoxysilyl-2-methyl-propanamine	437-720-3	227085-5	Xn; R41	Xi R: 41 S: (2-)26-39	
612-261-00-5	dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)aniline	441-190-9	121451-0	Xn; R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)24-37-40-41	C ≥ 25 %: Xn, N; R22-43-50/53 ≤ C < 25 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53
612-265-00-5	(2-hydroxyethyl)-(2-hydroxypropyl)ammonium acetate	444-360-0	191617-1	R52-53	R: 52/53 S: 61	
612-266-00-0	chloro-4-(3-fluorobenzyloxy)aniline	445-590-4	202197-2	Muta. Cat. 3; R68 Xn; R22-48/22 N; R50-53	Xn; N R: 22-48/22-68-50/53 S: (2-)22-36/37-60-61	
612-267-00-6	(hydrogenated tallow C ₁₆₋₁₈ -alkyl)hydroxylamine	418-370-0	—	R43 R53	Xi R: 43-53 S: (2-)36/37-61	
612-269-00-7	mixture of: 1-[di(4-octylphenyl)aminomethyl]-5-methyl-1H-benzotriazole;	420-720-2	—	R53	R: 53 S: 22-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	1-[di(4-octylphenyl)aminomethyl]-4-methyl-1 <i>H</i> -benzotriazole; mixture of: <i>N</i> -[(5-methyl-1 <i>H</i> -benzotriazol-1-yl)methyl]-4-octyl- <i>N</i> -(4-octylphenyl)aniline; <i>N</i> -[(4-methyl-1 <i>H</i> -benzotriazol-1-yl)methyl]-4-octyl- <i>N</i> -(4-octylphenyl)aniline						
612-270-0052	5-azetidine-2-carboxylic acid 4-cyanobenzylamide hydrochloride	433-010-2	—	Xn; R22 R43 R52-53	Xn R: 22-43-52/53 S: (2-)22-36/37-61		
612-271-0018	Mixture of: ethyl 2-((4-(5,6-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate; ethyl 2-((4-(6,7-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate	434-970-5	160987-5	R53	R: 53 S: 61		
612-272-0013	Iron(III) monohydrate (η-6-2-(2-(1,2-dicarboxylatoethylamino)ethylamino)butane-1,4-dioato(4-))iron(3+) monohydrate	435-210-5	—	N; R51-53	N R: 51/53 S: 61		
612-273-0019	Diethyl (rapeseed oil), bis(2-hydroxyethyl)ammonium fluoride	435-650-8	—	Xn; R22 C; R35 N; R50-53	C; N R: 22-35-50/53 S: (1/2-)26-36/37/39-45-60-61		
612-274-0045	(S)-1-[2-amino-1(4-	445-750-3	—	Xn; R22 Xi; R41 R43	Xn R: 22-41-43-52/53		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	methoxyphenyl)ethyl]cyclohexanol acetate			R52-53	S: (2-)22-24-26-37/39-61	
612-275-00-X	fatty acids, C ₁₈ -unsatd., dimers, reaction products with 1-piperazineethanamine and tall oil	447-880-6206565-89		Xi; R38-41 R43 N; R50-53	Xi; N R: 38-41-43-50/53; S: (2-)23-26-36/37/39-60-61	C ≥ 20 %: R38-41-43-50/53; R38-41-43-50/53 ≤ C < 20 %: Xi, N; R41-43-50/53 5 % ≤ C < 10 %: Xi, N; R36-43-50/53 2,5 % ≤ C < 5 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53
612-276-00-5	amino-4-[(4-amino-2-sulfofenyl)amino]-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, disodium salt, reaction products with 2-[[3-[(4,6-dichloro-1,3,5-triazin-2-yl)ethylamino]phenyl]sulfonyl]ethyl hydrogen sulfate,	451-430-4500717-36		Xi; R41 R43 R52-53	Xi R: 41-43-52/53 S: (2-)22-24-26-36/37/39-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	sodium salts						
612-277-00	Mixture of: 4-amino-3-(4-ethenesulfonyl-2-sulfonatophenylazo)-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonooxyethanesulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)naphthalene-2,7-disulfonate potassium/sodium; 4-amino-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonooxyethanesulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-3-(2-sulfonato-4-(2-sulfonooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate potassium/sodium	451-440-9	586372-44	Xi; R41	Xi R: 41 S: (2-)22-26-39		
612-278-00	16idium bromide; 3,8-diamino-1-ethyl-6-phenylphenantridinium bromide	214-984-6	1239-45-8	Muta. Cat. 3; R68 T+; R26 Xn; R22	T+ R: 22-26-68 S: (1/2-)28-36/37-45-63		
612-279-00	(R,S)-2-amino-3,3-dimethylbutane amide	447-860-7	144177-62	Repr. Cat. 3; R62 Xn; R48/22 Xi; R36/38 R43	Xn R: 36/38-43-48/22-62 S: (2-)22-26-36/37		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

613-283-00	Beconazole; 1-[4-[4- [[<i>(2SR,4RS)</i>]-2- (2,4- dichlorophenyl)-2- (imidazol-1- ylmethyl)-1,3- dioxolan-4- yl]methoxy]phenyl]piperazin-1- yl]ethanone	265-667-465277-42		Repr. Cat. 2; R60 T; R25 Xn; R48/22 N; R50-53	T; N R: 60-25-48/22-50/53 S: 53-45-60-61		
613-284-00	Metconazole (ISO); (<i>1RS,5RS</i> ; <i>1RS,5SR</i>)-5- (4- chlorobenzyl)-2,2- dimethyl-1- (<i>1H</i> -1,2,4- triazol-1- ylmethyl)cyclopentanol	—	125116-23	Repr. Cat. 3; R63 Xn; R22 N; R51-53	Xn; N R: 22-63-51/53 S: (2-)36/37-46-61		
613-285-00	7 hydroxybenzotriazol-2- anhydrous; [1] 1- hydroxybenzotriazole, monohydrated [2]	219-989-71492-95-21	219-989-71492-95-21	E1 R2 R2 R2333-53-9 [2]	E R: 2 S: 16-35		
613-286-00	Potassium 1- methyl-3- morpholinocarbonyl-4- [3-(1- methyl-3- morpholinocarbonyl-5- oxo-2- pyrazolin-4- ylidene)-1- propenyl]pyrazole-5- olate; [containing < 0,5 % N,N- dimethylformamide (EC No 200-679-5)]	418-260-2183196-57	418-260-2183196-57	R43	Xi R: 43 S: (2-)24-37		
613-286-01 X	Potassium 1- methyl-3- morpholinocarbonyl-4- [3-(1- methyl-3- morpholinocarbonyl-5-	418-260-2183196-57	418-260-2183196-57	Repr. Cat. 2; R61 R43	T R: 61-43 S: 53-45		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate; [containing ≥ 0,5 % N,N-dimethylformamide (EC No 200-679-5)]						
613-287-00-83-	iodo-4-aminobenzyl)-1H-1,2,4-triazole	419-540-7160194-263			Xn; R22 R43 N; R51-53	Xn; N R: 22-43-51/53 S: (2-)24-37-61	
613-288-00-3-	bis(dimethylcarbamoyl)-imidazolium chloride	420-930-4135756-618			Xn; R22 Xi; R41 R52-53	Xn R: 22-41-52/53 S: (2-)22-26-37/39-61	
613-289-00-04-	chloro-2-fluoro-5-methylphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole	432-020-4142623-488			N; R50-53	N R: 50/53 S: 60-61	
613-290-00-4	hydroxy-7-(2-aminoethyl)-1,3-benzothiazol-2(3H)-one hydrochloride	432-470-1189012-933			Xi; R41 R43 N; R50-53	Xi; N R: 41-43-50/53 S: (2-)24-26-37/39-60-61	
613-291-00-4- X	dihydro-4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one	434-820-9106461-418			Xn; R48/22 N; R50-53	Xn; N R: 48/22-50/53 S: (2-)22-36-60-61	
613-292-00-5',N	'-tris(2-methyl-2,3-epoxypropyl)-perhydro-2,4,6-	435-010-826157-73			Muta. Cat. 3; R68 R52-53	Xn R: 68-52/53 S: (2-)36/37-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	oxo-1,3,5-triazine					
613-293-00-0	(4- <i>tert</i> -butylphenyl)-6-cyano-5-[bis(ethoxycarbonylmethyl)carbamoyloxy]-1 <i>H</i> -pyrrolo[1,2- <i>b</i>][1,2,4]triazole-7-carboxylic acid 2,6-di- <i>tert</i> -butyl-4-methylcyclohexylester	448-050-6444065-11	653	R: 53 S: 61		
613-294-00-6	hexyldecanoic acid [4-(6- <i>tert</i> -butyl-7-chloro-1 <i>H</i> -pyrazolo[1,5- <i>b</i>][1,2,4]triazol-2-yl)phenylcarbamoyl]methylester	448-260-8379268-96	653	R: 53 S: 61		
613-295-00-1	1-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[<i>c,f</i>][1,2]thiazepine hydrochloride	448-720-8363138-44	Xn; R22 Xi; R41 R52-53	Xn R: 22-41-52/53 S: (2-)22-26-39-61		
613-296-00-7	pentapotassium 2-(4-(5-[1-(2,5-disulfonatophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-methyl-1,3-pentadienyl)-3-methylcarbamoyl-5-oxidopyrazol-1-yl)benzene-1,4-disulfonate	418-270-7	R43 R52-53	Xi R: 43-52/53 S: (2-)24-37-47-61		
613-297-06-2	(2-bromophenyl)-2- <i>tert</i> -	420-820-6	R10 Xn; R22	Xn; N		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	butyl-2H-tetrazole			N; R51-53	R: 10-22-51/53 S: (2-)16-61	
613-298-0018	(6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(4-phenylazo)-1H-pyridin-2-one)ethylene dilactate	421-560-6	—	Xn; R48/22 Xi; R41 N; R51-53	Xn; N R: 41-48/22-51/53 S: (2-)22-26-36/39-61	
613-299-0011	main component 1 (isomer 1): 2-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluoro-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt; main component 1 (isomer 2): 2-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-	422-610-1	—	Xi; R41	Xi R: 41 S: (2-)22-26-39	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt; main component 2: 2,3-bis-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt; main component 3: 2,3-bis-{6-fluoro-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt					
613-300-00-7	imidazol-1-yl-	434-120-3	—	R43 R53	Xi R: 43-53 S: (2-)24-37-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	octadecan-2-ol						
613-301-00	dimethyl-1- {[2- methoxy-5- (2- methyl- butoxycarbonyl)phenylcarbamoyl]- [2- octadecyl-1,1- dioxo-1,2,4- benzothiadiazin-3- yl]methyl} imidazole-4,5- dicarboxylate	443-910-7	—	R53	R: 53 S: 61		
613-302-00	sodium 2-(5- carbamoyl-1- ethyl-2- hydroxy-4- methyl-6- oxo-1,6- dihydro- pyridine-3- ylazo)-4- (4- fluoro-6- (4-(2- sulfonyloxy- ethylsulfonyl)- phenylamino)-1,3,5- triazine-2- ylamino)benzene sulfonate	432-980-4	243858-60	Xn; R41	Xi R: 41 S: (2-)22-26-39		
613-303-00	β-1- methyl-2- (4- phenoxyphenoxy)ethoxy)pyridine	429-800-1	95737-68	N; R50-53	N R: 50/53 S: 60-61		
613-304-00	2,3- dihydroxy-2,3- dihydro-1 <i>H</i> - indolium bromide	421-170-6	138937-28	Xn; R22 Xi; R41	Xn R: 22-41 S: (2-)22-26-39		
613-305-00	4- hydroxy-4- octyloxyphenyl)-2 <i>H</i> - benzotriazole	448-630-9	3147-77-1	R53	R: 53 S: 61		
613-306-00 X	2,5- dioxopyrrolidin-1- yl)-9 <i>H</i> -	433-520-5	82911-69	Xn; R22 R43	Xn; N R: 22-43-51/53		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	fluoren-9-ylmethyl carbonate			N; R51-53	S: (2-)24-37-61	
613-307-00-15	thianidin (ISO); 3-[(2-chloro-1,3-thiazol-5-yl)methyl]-2-methyl-1-nitroguanidine	—	210880-92	Xn; R22 N; R50-53	Xn; N R: 22-50/53 S: (2-)46-60-61	C ≥ 25 %: Xn, N; R22-50/53 0,5 % ≤ C < 25 %: N; R50/53 0,25 % ≤ C < 2,5 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53
613-308-00-0	amino-5-methylthiazole	423-800-57	305-71-7	Xn; R22-48/22 N; R50-53	Xn; N R: 22-48/22-50/53 S: (2-)22-36-60-61	
613-309-00-6	methyl-3-phenyl-1-piperazine	431-180-25	271-27-2	Xn; R21/22 Xi; R38-41 R52-53	Xn R: 21/22-38-41-52/53 S: (2-)26-36/37/39-61	
613-310-00-1	(3S,4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxy-methyl)-N-benzylpiperidine hydrochloride	432-360-31	05813-13	Xn; R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)22-24-37-60-61	
613-311-00-7	methyl-5-nitrophenyl-guanidine	435-500-11	52460-07	Xn; R22 Xi; R36 R43 R52-53	Xn R: 22-36-43-52/53 S: (2-)22-24-26-37-61	
613-312-00-24	methyl-2-phenyl-1-	420-200-5	—	Xn; R22 Xi; R41 R43 R52-53	Xn R: 22-41-43-52/53	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	piperazinyl)benzenemethanol monohydrochloride				S: (2-)22-26-36/37/39-61		
613-313-00-84-	(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)-1H-isoindole-1,3(2H)-dione	442-780-9173838-67052-53			R: 52/53 S: 61		
613-314-00-3	decyloxazolidin-2-one; 4-decyl-1,3-oxazolidin-2-one	443-770-77693-82-5		N; R50-53	N R: 50/53 S: 22-24-60-61		
613-315-00-9	potassium 4-[5-[3-carboxylato-4,5-dihydro-5-oxo-1-(4-sulfonatophenyl)pyrazol-4-ylidene]-3-(piperidinocarbonyl)penta-1,3-dienylidene]-5-hydroxy-1-(4-sulfonatophenyl)pyrazole-3-carboxylate	430-390-1—		Xn; R20 R52-53	Xn R: 20-52/53 S: (2-)25-61		
613-316-00-4	1,1-dimethylpropane tri(3-aziridinylpropanoate); (TAZ)	257-765-052234-82-9		Muta. Cat. 3; R68 Xi; R41 R43	Xn R: 41-43-68 S: 26-36/37/39-42		
615-044-00-1	chlorophenylisocyanate	203-176-9104-12-1		T+; R26 Xn; R22 Xi; R37/38-41 R42 N; R50-53	T+; N R: 22-26-37/38-41-42-50/53 S: (1/2-)26-28-36/37/39-45-63-60-61		
615-045-00-7-	7-methylene bis(3-chloro-2,6-diethylphenylisocyanate)	420-530-1—		R42/43 R53	Xn R: 42/43-53 S: (2-)23-24-37-45-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

616-126-00-X	methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide	423-960-6	139756-0	Xn; R22-48/22 R52-53	Xn R: 22-48/22-52/53 S: (2-)22-36/37-61		
616-164-00-017	dimoxystrobin (ISO); (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide	—	149961-5	Carc. Cat. 3; R40 Repr. Cat. 3; R63 Xn; R20 N; R50-53	Xn; N R: 20-40-63-50/53 S: (2-)36/37-40/60-61	C ≥ 25 %: Xn, N; R20-40-63-50/53 < 25 %: Xn, N; R40-63-50/53 2,5 % ≤ C < 5 %: Xn, N; R40-50/53 1 % ≤ C < 2,5 %: Xn, N; R40-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52-53	
616-165-00-021	flubutamid (ISO); (RS)-N-benzyl-2-(α,α,α,4-tetrafluoro-m-tolyoxy)butyramide	—	113614-0	N; R50-53	N R: 50/53 S: 60-61	C ≥ 0,25 %: N; R50/53 0,025 % ≤ C < 0,25 %: N; R51/53 0,0025 % ≤ C < 0,025 %: R52/53	
616-166-00-028	azofamid (ISO); 4-chloro-2-cyano-N,N-dimethyl-5-p-tolylimidazole-1-sulfonamide	—	120116-8	N; R50-53	N R: 50/53 S: 60-61	C ≥ 2,5 %: N; R50/53 0,25 % ≤ C < 2,5 %:	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						N; R51-53 0,025 % ≤ C < 0,25 %: R52/53	
616-167-00-3	N- dibutyl- (2,5- dihydro-5- thioxo-1H- tetrazol-1- yl)acetamide	418-290-6168612-06	418-290-6168612-06	Xi; R36 R43	Xi R: 36-43 S: (2-)24-26-37		
616-168-00-9	dimethylcarbamoyl-4- (2- sulfonatoethyl)pyridinium	418-440-0136997-71	418-440-0136997-71	R23	Xi R: 43 S: (2-)22-24-37		
616-169-00-44	(2,2- dimethyl- propanamido)]phenylazo-3- (2- chloro-5- (2-(3- pentadecylphenoxy)butylamido)anilino)-1- (2,4,6- trichlorophenyl)-2- pyrazoline-5- one	420-220-492771-56	420-220-492771-56	R43 R53	Xi R: 43-53 S: (2-)24-37-61		
616-170-00-2 X	(2R)-2- amino-2- phenylacetamide	420-370-06485-67-2	420-370-06485-67-2	Xi; R36 R43	Xi R: 36-43 S: (2-)22-26-36/37		
616-171-00-6	para- chlorophenyl)glycineamide	420-830-0102333-75	420-830-0102333-75	Xi; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39		
616-172-00-0	(2,2,6,6- tetramethyl-1- oxypiperidin-4- yl)acetamide; (4- acetamido-2,2,6,6- tetramethyl-1- piperidinyl)oxidanyl	423-840-314691-89	423-840-314691-89	Xn; R22	Xn R: 22 S: (2-)22		
616-174-00-1	butyl-1,3- diazaspiro[4.4]non-1-	424-560-4151257-01	424-560-4151257-01	Xn; R22 Xi; R36	Xn R: 22-36		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	en-4-one hydrochloride				S: (2-)22-26		
616-175-00-02	(2-hexyldecyloxy)benzamide	431-230-3202483-62R53			R: 53 S: 61		
616-176-00-2	<i>N,N</i> -bis(methoxyethyl)aminoacetanilide	432-530-724294-01Xn; R22 R52-53			Xn R: 22-52/53 S: (2-)22-24-61		
616-177-00-38	(4-(2-(butyl-(4-methylphenylsulfonyl)amino)phenylthio)-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazole-3-ylamino)-4-chlorophenyl)tetradecanamide; <i>N</i> -[3-({4-[(2-{butyl[(4-methylphenyl)sulfonyl]amino}phenylthio)]-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-3-yl}amino)-4-chlorophenyl]tetradecanamide	432-970-1217324-98R63			R: 53 S: 61		
616-178-00-35	(bis(2-methoxyethyl)amino)-2-((2-cyano-4,6-dinitrophenyl)azo)phenyl)acetamide	434-500-952583-35R53			R: 53 S: 22-61		
616-179-00-9	chloro- <i>N</i> -(4-methylphenyl)acetamide	435-170-916634-82Xi; R41 R43 N; R50-53			Xi; N R: 41-43-50/53 S: (2-)22-26-36/37/39-60-61		
616-180-00-4	<i>N,N</i> -(dimethylamino)thioacetamide hydrochloride	435-470-127366-72Repr. Cat. 2; R61 N; R50-53			T; N R: 61-50/53 S: 53-45-60-61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

616-181-00-X	4'-methyldecane-1-sulfonanilide	435-490-917417-32	N; R50-53	N R: 50/53 S: 60-61		
616-182-00-5	(1,3-dimethylbutylidene)-3-hydroxy-2-naphthohydrazide	435-860-1214417-9	IR43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
616-183-00-0	dodecyl-4-methoxybenzamide	442-340-61854-15-5	R53	R: 53 S: 61		
616-184-00-6	methyl-N-(5,8,13,14-tetrahydro-5,8,14-trioxonaphth[2,3-c]acridin-6-yl)benzamide	442-560-2105043-5	R53	R: 53 S: 61		
616-186-00-7	N,N'-(2-chloro-1,4-phenylene)bis(3-oxobutaneamide)	443-010-453641-10	R52-53	R: 52/53 S: 61		
616-188-00-8	5,5-dimethyl-2,4-dioxooxazolidin-3-yl)-4,4-dimethyl-3-oxo-N-(2-methoxy-5-octadecanoylamino)phenyl)pentanoic acid amide	443-980-9221215-20	IR43 R53	Xi R: 43-53 S: (2-)24-37-61		
616-189-00-3	(bis-(2-methoxyethyl)-amino]-2-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-phenyl]acetamide	444-780-4452962-9	R53	R: 53 S: 61		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

616-190-009	decyl-4-nitrobenzamide	445-880-064026-19	R53	R: 53 S: 61		
616-191-004	ethyl- <i>N</i> -methyl- <i>N</i> -(3-methylphenyl)butanamide	446-190-2406488-30	Xn; R22 Xi; R36/38 R43 N; R51-53	Xn; N R: 22-36/38-43-51/53 S: (2-)24-26-37-61		
616-192-00X	[2-(3-butoxypropyl)-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]-5'- <i>tert</i> -butyl-2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-2'-[(2-ethylhexyl)thio]acetanilide	448-060-0727678-39	R53	R: 53 S: 61		
616-193-005	[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1 <i>H</i> -isoindol-5-ylazo)-5-diethylamino-phenyl]acetamide	449-940-7368450-39	R53	R: 53 S: 61		
616-194-000	diethoxy- <i>N,N</i> -dimethylacetamide	449-950-134640-92	Ki; R36	Xi R: 36 S: (2-)26		
616-196-001	sodium salt of 1-hydroxy-4-(β-(4-(1-hydroxy-3,6-disulfo-8-acetylamino-2-naphthylazo)phenoxy)ethoxy)- <i>N</i> -dodecyl-2-naphthamide	419-990-4—	N; R50-53	N R: 50/53 S: 60-61		
616-197-007	mixture of: potassium <i>N</i> -[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-	422-500-1—	Xn; R48/22	Xn R: 48/22 S: (2-)22-36		

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	heptadecafluorooctane sulfonamidate; N-[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamide					
616-198-00	3-bis[12-hydroxy-octadecamide-N-methylene]-benzene	423-300-7	—	R43 R53	Xi R: 43-53 S: (2-)24-37-61	
616-200-00	mixture of: N,N'-ethane-1,2-diylbis(hexanamide); 12-hydroxy-N-[2-[(1-oxyhexyl)amino]ethyl]octadecanamide; N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide)	432-430-3	—	R43 R53	Xi R: 43-53 S: (2-)24-37-61	
616-201-00	27-hydroxyoctadecanoic acid, reaction products with 1,3-benzenedimethanamine and hexamethylenediamine	432-840-2	220926-9	Xn; R20 R53	Xn R: 20-53 S: (2-)22-61	
616-202-00	mixture of: 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(2,4-dimethylphenyl)]-3-oxo-butanamide; 2-[[[3,3'-dichloro-4'-[[1[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-	434-330-5	—	Carc. Cat. 3; R40 R43 R53	Xn R: 40-43-53 S: (2-)36/37-61	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	yl]azo]-N-(2-methylphenyl)-3-oxo-butanamide; 2-[[[3,3'-dichloro-4'-[[1[[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-carboxylphenyl)-3-oxo-butanamide					
616-203-00	Mixture of: N-[5-[bis-(2-methoxyethyl)amino]-2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl-azo)phenyl]acetamide; N-[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)5-diethylaminophenyl]acetamide	442-280-0	—	R53	R: 53 S: 61	
616-204-00	N,N'-(methylenedi-4,1-phenylene)bis[N'-octylurea]	451-060-3	122886-5	R53	R: 53 S: 61	
617-022-00	Mixture of: 1,2-dimethylpropylidene dihydroperoxide; dimethyl 1,2-benzenedicarboxylate	442-480-8	—	O; R7 Xn; R22 C; R34 R43 N; R51-53	O; C; N R: 7-22-34-43-51/53 S: (1/2-)3/7-14-26-36/37/39-45-50-61	
647-017-00	Case	420-150-4	480498-15	R42	Xn R: 42	

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After
IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					S: (2-)23-45	
--	--	--	--	--	-----------------	--